



# **King's Research Portal**

DOI: 10.1210/endocr/bqac131

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

Lin, Y. F., Schang, G., Buddle, E. R. S., Schultz, H., Willis, T. L., Ruf-Zamojski, F., Zamojski, M., Mendelev, N., Boehm, U., Sealfon, S. C., Andoniadou, C. L., & Bernard, D. J. (2022). Steroidogenic factor 1 regulates transcription of the inhibin B co-receptor in pituitary gonadotrope cells. *Endocrinology*, *163*(11), [bqac131]. https://doi.org/10.1210/endocr/bgac131

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

#### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 08. Oct. 2023

- 1 Steroidogenic factor 1 regulates transcription of the inhibin B co-receptor in pituitary
- 2 gonadotrope cells

3

- 4 Yeu-Farn Lin<sup>1</sup>, Gauthier Schang<sup>1</sup>, Evan R. S. Buddle<sup>1</sup>, Hailey Schultz<sup>2</sup>, Thea L. Willis<sup>3</sup>,
- 5 Frederique Ruf-Zamojski<sup>4</sup>, Michel Zamojski<sup>4</sup>, Natalia Mendelev<sup>4</sup>, Ulrich Boehm<sup>5</sup>, Stuart C.
- 6 Sealfon<sup>4</sup>, Cynthia L. Andoniadou<sup>3</sup>, Daniel J. Bernard<sup>1,2</sup>

7

- <sup>1</sup>Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
- <sup>2</sup>Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada
- <sup>3</sup>Centre for Craniofacial and Regenerative Biology, King's College London, London, UK
- <sup>4</sup>Department of Neurology, Center for Advanced Research on Diagnostic Assays, Icahn School
- of Medicine at Mount Sinai, New York, New York, USA
- <sup>4</sup>Department of Experimental Pharmacology, Center for Molecular Signaling, Saarland
- 14 University School of Medicine, Homburg, Germany

15

Short title: SF-1 regulates *Tgfbr3l* transcription

17

18 Key words: Transcription, inhibin, receptor, pituitary, knockout mouse, cell line

19

- 20 Corresponding author: daniel.bernard@mcgill.ca; Tel. 514-554-6735; Department of
- 21 Pharmacology and Therapeutics, 3655 Promenade Sir William Osler, McGill University,
- 22 Montreal, Quebec, Canada; ORCID ID: 0000-0001-5365-5586

23

© The Author(s) 2022. Published by Oxford University Press on behalf of Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<a href="https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model">https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model</a>)

Funding: Canadian Institute of Health Research project grant PJT-162343 (DJB); National 1

Institute of Health Grant DK46943 (SCS); Medical Research Council (MRC) project grant 2

MR/T012153/1 (CLA); Dr. Samuel Solomon Fellowship in Endocrinology (McGill University 3

Health Centre) (YFL and GS); Canadian Institute of Health Research Master's Graduate

Scholarship (YFL and HS); Canadian Institute of Health Research Doctoral Research Award

(GS); Fonds de Recherche du Québec - Santé, Master's Scholarship (GS); "Cell Therapies and

Regenerative Medicine" Four-Year Welcome Trust PhD Training Programme (King's College

8 London) (TLW)

4

5

6

7

9

10

Disclosures: The authors have nothing to disclose

## Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

The inhibins control reproduction by suppressing follicle-stimulating hormone synthesis in pituitary gonadotrope cells. The newly discovered inhibin B co-receptor, TGFBR3L, is selectively and highly expressed in gonadotropes in both mice and humans. Here, we describe Tqfbr3I/TGFBR3L our initial characterization of mechanisms controlling cell-specific transcription. We identified two steroidogenic factor 1 (SF-1 or NR5A1) cis-elements in the proximal Tgfbr3l promoter in mice. SF-1 induction of murine Tgfbr3l promoter-reporter activity was inhibited by mutations in one or both sites in heterologous cells. In homologous cells, mutation of these cis-elements or depletion of endogenous SF-1 similarly decreased reporter activity. We observed nearly identical results when using a human TGFBR3L promoter-reporter. The Tgfbr3I gene was tightly compacted and Tgfbr3I mRNA expression was essentially absent in gonadotropes of SF-1 (Nr5a1) conditional knockout mice. During murine embryonic development, Tgfbr3I precedes Nr5a1 expression, though the two transcripts are fully colocalized by embryonic day 18.5 and thereafter. Collectively, these data indicate that SF-1 directly regulates Tgfbr3I/TGFBR3L transcription and is required for post-natal expression of the gene in gonadotropes.

#### Introduction

Reproduction is controlled by intricate endocrine feedforward/feedback loops between the brain, pituitary gland, and the gonads. Follicle-stimulating hormone (FSH) is a dimeric glycoprotein produced by pituitary gonadotrope cells that regulates ovarian follicle development and estrogen biosynthesis in females and spermatogenesis in males (1, 2). FSH production is stimulated by gonadotropin-releasing hormone (GnRH) from the brain and by transforming growth factor  $\beta$  (TGF $\beta$ ) ligands, such as the activins, which are currently thought to act in an autocrine/paracrine manner in the pituitary to stimulate transcription of the FSH $\beta$  subunit (3).

FSH also stimulates the synthesis and secretion of activin-related TGFβ ligands, known as the inhibins, from the gonads. The ovaries produce inhibins A and B (4-6), whereas the adult testes in most mammalian species produce inhibin B alone (7). Inhibins feedback to gonadotropes to suppress FSH production by competitively binding to activin receptors (8). Inhibin binding to these receptors is enhanced by transmembrane co-receptors. The TGFβ type III receptor (TGFBR3), also known as betaglycan, can mediate the actions of both inhibins (8, 9); however, conditional deletion of the *Tgfbr3* gene in gonadotropes principally impairs inhibin A, leaving inhibin B action intact (10). This observation led to the recent discovery of a betaglycan-like protein, TGFBR3L, which functions as a specific inhibin B co-receptor in gonadotropes (11).

Whereas betaglycan is broadly expressed, including in the pituitary, gonads, and adrenal glands (12), *Tgfbr3l/TGFBR3L* expression appears to be restricted to gonadotropes in adult mice and humans (11, 13-15). The mechanisms conferring this cell-specific expression have not been elucidated. Here, we report that the nuclear receptor, steroidogenic factor 1 (SF-1, product of the *Nr5a1* gene), regulates *Tgfbr3l/TGFBR3L* transcription via conserved regulatory elements in the proximal promoter. *In vivo*, SF-1 is necessary for the maintenance, but not the initial expression of *Tgfbr3l* in gonadotropes.

#### **Materials and methods**

## **DNA** constructs

The wild-type murine -999/+1 *Tgfbr3I* and human -996/+1 *TGFBR3L* luciferase promoter-reporters were produced by PCR amplification of genomic DNA (see Table 1 for primers). The PCR products were ligated into pGL3-Basic (Promega, Madison, WI, USA) or pA3-luc (16). The murine SF-1 expression construct was described previously (17). The mutant promoter-reporters were constructed using the QuikChange protocol with primers described in Table 1. All constructs were confirmed by sequencing (Génome Québec, Montreal, QC, CAN).

## 5' Rapid Amplification of cDNA Ends (RACE)

5' RACE was performed using the FirstChoice RLM-RACE kit (AM1700, Invitrogen, Waltham, MA, USA), following the manufacturer's protocol. Briefly, 10 μg of intact 5' capped mRNA from the pituitary of a male C57BL6 mouse was decapped and ligated to the 5' RACE adaptor. The ligated mRNA was reverse transcribed with MMLV-RT using a gene-specific primer located in exon 4 (see Table 1). Nested PCR was performed on the resulting cDNA using adaptor-specific forward primers and gene-specific reverse primers (see Table 1). PCR products were ligated into the pGEM-T Easy vector (A1360, Promega) and sequenced (Génome Québec, Montreal, QC, CAN).

## Cell culture and promoter-reporter assays

All cells were cultured at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Human embryonic kidney (HEK) 293T cells (ATCC CRL-3216; RRID: CVCL\_0063; provided by Dr. Terry Hébert, McGill University) were cultured in DMEM (319-005-CL, Wisent, St-Bruno, QC, CAN) supplemented with 5% (v/v) fetal bovine serum (FBS; 098150, Wisent). Immortalized murine

gonadotrope-like LβT2 cells (18) (RRID: CVCL\_0398; provided by Dr. Pamela Mellon, University of California, San Diego, CA, USA) were cultured in DMEM supplemented with 10% (v/v) FBS.

Promoter-reporter assays were performed as previously described (16). Briefly, HEK293T and LβT2 cells were seeded at densities of 50,000 and 150,000 cells per well, respectively, in 48-well plates. The following day, HEK293T cells were transfected using PEI at a ratio of 1:3 (μg DNA to μg PEI). LβT2 cells were transfected using Lipofectamine 3000 (L3000015, ThermoFisher Scientific, Burlington, ON, CAN) following the manufacturer's protocol. Control (D-001210-05) and Nr5a1 (D-051262-01) short interfering RNAs (siRNAs) were purchased from Dharmacon (Lafayette, CO, USA). For assays where siRNAs and the murine promoter-reporter were co-transfected, the pA3-luc backbone was used. Twenty-four hours after transfection, cells were serum starved for an additional 24 h. After starvation, cells were lysed in 50 µl/well passive lysis buffer [25 mM Tris-phosphate (pH 7.8), 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1 mg/mL bovine serum albumin (BSA), 2 mM EDTA] for 10 min at room temperature with agitation. Twenty µl of cell lysis supernatant was combined with 100 µl assay buffer [15 mM potassium phosphate (pH 7.8), 25 mM glycylglycine, 15 mM MgSO<sub>4</sub>, 4 mM EDTA, 2 mM ATP, 1 mM DTT, 0.04 mM D-luciferin], and luciferase activity was measured on an Orion II microplate luminometer (Berthold Detection Systems, Oak Ridge, TN, USA). All experiments were performed in technical triplicates and the experiments repeated as indicated in the figures.

## DNA affinity purification assay and immunoblot

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Thirty µI of Dynabeads® M-280 (11205D, Dynal, Invitrogen) were washed three times with 2x B&W buffer [10 mM Tris, pH 7.5, 1 mM EDTA, 2 M NaCl], then 10 µM each of wild-type or mutant biotinylated double-stranded probe (see Table 2) were incubated with the beads in 1x B&W buffer at room temperature for 15 min. Beads were washed twice with 2x B&W buffer and

once with 1x binding buffer [5% (v/v) glycerol, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 0.15% Triton X-100, 100 mM NaCl, 4 mM MgCl<sub>2</sub>], then blocked for 30 min at room temperature using 1% (w/v) BSA in binding buffer, and lastly resuspended in 50  $\mu$ l of 1x binding buffer. L $\beta$ T2 cells were grown until confluent in 10 cm plates and harvested using 1 mL of DNAP lysis buffer [300 mM NaCl, 20 mM Tris–HCl (pH 7.5), 1% (v/v) Triton X-100, 1 mM PMSF, 2  $\mu$ g/ml leupeptin and aprotinin]. One hundred  $\mu$ l of clarified lysate was combined in a 500  $\mu$ l reaction with 100  $\mu$ l of 5x binding buffer, 10  $\mu$ l of 0.5  $\mu$ g/ $\mu$ l salmon sperm DNA (Invitrogen, 15632011), and 50  $\mu$ l of DNA-bound streptavidin magnetic beads. The reaction was incubated at 4°C for 2 h with agitation, followed by 5 washes in 1x binding buffer. Bound proteins were eluted in 40  $\mu$ l of 0.1% SDS at 100°C for 5 min.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Ten µl of 5x Laemmli buffer [250 mM Tris pH 6.8, 10% SDS, 50% glycerol, 0.02% bromophenol blue, and 10% β-mercaptoethanol] was added and eluted proteins were resolved by sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) on a 10% resolving gel prepared using a 30% (w/w) acrylamide/bis-acrylamide (29:1) solution in running buffer (25 mM Tris, 250 mM glycine, 0.1% SDS, pH 8.3). Proteins were transferred to Protran nitrocellulose membranes (GE 10600001, Millipore Sigma, Oakville, Ontario, CA) in Towbin buffer (25 mM Tris, 192 mM glycine, pH 8.3, 20% methanol), blocked with 5% milk (w/v) in Trisbuffered saline [TBS; 150 mM NaCl, 10 mM Tris (pH 8.0)] containing 0.05% (v/v) Tween 20 (TBST) and incubated overnight at 4°C with agitation with an antibody against SF-1 diluted in blocking buffer (1:1000; D1Z2A; Cell Signaling Technology, Danvers, MA, USA: RRID:AB\_2798030). The next day, membranes were washed in TBST and incubated in horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:5,000; AP182P; Millipore Sigma; RRID:AB 92591] in blocking buffer for 1 h at room temperature with agitation. Membranes were once again washed in TBST, and bands were visualized using enhanced chemiluminescence substrate (NEL105001, PerkinElmer, Waltham, MA, USA) and an Amersham Imager 600 (GE Healthcare, Chicago, IL, USA).

## **Chromatin Immunoprecipitation**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

L $\beta$ T2 cells were seeded at a density of 1.5 million cells/well in a 6-well plate. After three days, formaldehyde was added to a final concentration of 1%, and crosslinking was performed for 10 min at room temperature. The reaction was then quenched with 125 mM glycine for 5 min at room temperature. Cells were scraped and collected in 1 mL of ice-cold PBS and centrifuged at 800 x g for 10 minutes at 4°C. The cell pellet was then resuspended in 100  $\mu$ l of Nuc101 EZ lysis buffer (NUC101, Millipore Sigma) with protease inhibitor cocktail (04693116001, Millipore Sigma) and 1 mM PMSF for 5 minutes on ice, then centrifuged at 500 x g for 5 minutes at 4°C. Supernatant was discarded and the pellet washed in Nuc101 EZ lysis buffer as above. The nuclei were then divided into three tubes for digestion.

Nuclei (in 50 µl of Nuc101 EZ lysis buffer) were mixed with 6 µl of 10x MNase buffer [10] mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 50% glycerol], 0.44 µl of 200 mM DTT, and 1 µl of diluted MNase (M0247S, New England Biolabs, Ipswich, MA, USA; diluted 1:10 in MNase reaction buffer [50 mM Tris-HCl (pH 7.9], 5 mM CaCl<sub>2</sub>]) in a total reaction volume of 60 µl. Nuclei were digested for 10 minutes at 37°C and the digestion was stopped with 6.6 µl of 100 mM EDTA and 6.6 µL of 1% Triton X-100/1% sodium deoxycholate. Chromatin was incubated on ice for 20 minutes, then 220 µL of complete IP buffer [20 mM Tris-HCl (pH 8), 2 mM EDTA, 150 mM NaCl, 0.1% Triton X-100, 1x protease inhibitor cocktail, 1 mM PMSF] was added. Ten percent of the chromatin was removed and kept as "input". NaCl was added to the input chromatin to a final concentration of 0.2 M and protein: DNA complexes were reverse-crosslinked overnight at 65°C. The next day, samples were incubated for 30 min at 37°C with 10 µg RNase A in a total volume of 200 µL followed by 1 hour at 55°C with 10 µg proteinase K in a total volume of 200 µL. DNA was extracted with phenol:chloroform:isoamyl alcohol and precipitated with sodium acetate and ethanol overnight at -20°C. The DNA was pelleted at 15,000 rpm at 4°C for 20 min, washed with 70% ethanol, dried, dissolved in 30 µl of 10 mM Tris-HCI (pH 8.0), and quantified using Nanodrop.

Ten µg of chromatin was precleared for 1 hour at 4°C with 10 µl of Dynal protein G beads (10003D, Invitrogen) on an end-over-end rotator, then incubated with protein G beads conjugated to either rabbit IgG (2729, Cell Signaling Technology; RRID: AB\_1031062) or rabbit anti-SF-1 (12800, Cell Signaling Technology; RRID:AB\_2798030) overnight. To conjugate the antibodies to the beads, 10 µl of beads (washed three times in complete IP buffer) were incubated with 1 µg of antibody in a total volume of 200 µl for 4 hours at 4°C on an end-overend rotator. The next day, after overnight incubation with chromatin, beads were sequentially washed with complete IP buffer (1 x 5 minutes at 4°C), low salt buffer [20 mM Tris-HCl (pH 8), 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS] (2 x 5 minutes at 4°C), and high salt buffer [20 mM Tris-HCl (pH 8), 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS] (1 x 5 minutes followed by 1 x 10 minutes at 4°C). Chromatin was eluted for 90 minutes at 65°C in 30 µl elution buffer (1 M NaHCO<sub>3</sub>, 1% SDS), then reverse-cross-linked, digested with RNase A and proteinase K, and extracted as described above.

Input and immunoprecipitated chromatin were analysed using qPCR (described below) using primers listed in Table 1.

## Generation of Nr5a1 conditional knockout mice

The *Nr5a1*<sup>fl/fl</sup> and *Gnrhr*<sup>JRES-Cre/IRES-Cre</sup> (GRIC) mice were previously described (19, 20). Cre-mediated recombination occurs in the germ line of male GRIC mice (21); thus, the GRIC allele was introduced via the female in all crosses. *Nr5a1*<sup>fl/fl</sup> males (Jackson Laboratory, 007041) (22) were crossed with GRIC females to produce *Nr5a1*<sup>fl/fl</sup>; *Gnrhr*<sup>GRIC/+</sup> progeny. *Nr5a1*<sup>fl/fl</sup> males were then crossed with *Nr5a1*<sup>fl/+</sup>; *Gnrhr*<sup>GRIC/+</sup> females to produce *Nr5a1*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup>; *Gnrhr*<sup>fl/fl</sup> (conditional knockout; cKO) animals. Genotyping and assessment of genomic recombination were conducted as previously described (23) (primers listed in Table 1). All animals were housed on a 12 h light: 12 h dark cycle and given access to food and water *ad libitum*. All animal work was conducted in accordance with federal and institutional guidelines

and with the approval of the McGill University Facility Animal Care Committee-DOW-A (protocol 5204).

## Organ collection and processing

Testes, seminal vesicles, ovaries, and uteri were dissected from control and cKO males at 8-10 weeks of age, and females at 9-10 weeks of age. Control females were collected at random points in the estrous cycle; cKO females were acyclic. All reproductive organs were weighed on an analytical balance. Pituitary glands were snap frozen in liquid nitrogen and stored at -80 °C until analysis.

#### Blood collection and hormone analyses

Blood was collected by cardiac puncture and allowed to coagulate at room temperature for approximately 30 min. Whole blood was centrifuged at 3000 rpm for 10 min at room temperature. Serum was collected and stored at -20°C until hormone analyses were conducted.

Serum FSH was assessed using a Milliplex kit (Millipore, MPTMAG-49K, custom-made for FSH only) following the manufacturer's instructions (lower detection limit: 23.7 pg/mL; dynamic range: 61.0 pg/mL to 250 000 pg/mL; limit of quantification [LOQ]: 61.0 pg/mL; intraassay coefficient of variation [CV] < 15%). Serum LH was measured using an in-house sandwich ELISA (24) (lower detection limit: 0.117 ng/mL; dynamic range: 0.117 ng/mL to 30 ng/mL; LOQ: 0.516 ng/mL; intra-assay CV < 10%) (25).

## RNA extraction and reverse transcription quantitative PCR (RT-qPCR)

RNA was extracted from tissues and LβT2 cells using TRIzol Reagent (15596018; Invitrogen, Waltham, MA, USA) following the manufacturer's protocol. Two hundred ng total RNA (concentration determined using Nanodrop spectrophotometer) were reverse transcribed

1 using random hexamers (C1181, Promega) and M-MLV reverse transcriptase (M1701,

2 Promega).

qPCR analysis was performed using EvaGreen (ABMMmix, Diamed, Missisauga, ON, CAN) and primers listed in Table 1 on a Corbett Rotorgene 600 instrument (Corbett Life Science, Sydney, NSW, AUS). mRNA levels were determined using the 2<sup>-ΔΔCT</sup> method. Gene expression was normalized to ribosomal protein L19 (*Rpl19*). All primers were validated for efficiency and specificity.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

3

4

5

6

7

## <u>Immunofluorescence</u>

Eleven-week-old mice were perfused with 4% paraformaldehyde (PFA) in PBS and dissected pituitaries were post-fixed in 4% PFA (P6148, Millipore Sigma) at room temperature for 2 hours. Samples were washed in PBS, cryoprotected with 30% sucrose overnight at 4°C, and embedded in OCT (95057-838, VWR International, Radnor, PA, USA). Frozen tissue was sectioned at a thickness of 10 µm using a Leica CM3050S cryostat, mounted on Fisherbrand Superfrost Plus slides (22-037-246, ThermoFisher Scientific), and stored at -80°C until use. Antigen retrieval was performed by incubating tissue in 0.01M citric acid-sodium citrate buffer (pH 6.0) with 0.05% Triton X-100 at 90-95°C for 30 min and cooled gradually until buffer temperature was between 30-40°C. Sections were washed with phosphate-buffered saline with 0.1%Tween (PBST), blocked in 5% BSA (in PBST) for 1 h at room temperature, then incubated overnight at 4°C with an antibody against SF-1 (described above) (1:100, diluted in blocking solution). Slides were washed in PBST, incubated at room temperature with Alexa Fluor 647 goat anti-rabbit (1:600; A27040, Invitrogen) for 1 h, washed in PBST, and mounted in Prolong Diamond Antifade Mountant with DAPI (P36966, Invitrogen). Fluorescent images were captured using a Leica SP8 confocal laser scanning microscope with a Leica HC PL CS2 63X/1.4 NA oil objective.

## Single-cell analyses

Pituitaries were collected from 10- to 12-week-old control and cKO males, immediately snap frozen in liquid nitrogen, and stored at -80°C until analysis. Nuclei were isolated from individual pituitaries and single nucleus assay for transposase-accessible chromatin (snATAC-seq) was performed using the Single Cell ATAC reagent kit V1 (10x Genomics) as described (13). snATAC-seq data were processed using the Cell Ranger-ATAC pipeline version 1.2.0 (10X Genomics). Samples processed in multiple wells were combined using the *aggr* function. Clustering was performed in *Signac* (26) following standard procedures, and clusters were annotated based on chromatin accessibility at the promoter of known pituitary cell type markers (13). We used *igvtools* 2.3.32 (27) to generate chromatin accessibility tracks for the gonadotropes using a window size of 400 base-pairs per cut-site. Tracks were normalized to both the number of gonadotropes and the median number of fragments per gonadotrope in each sample. snATAC-seq datasets can be found in the GEO data repository under the accession number GSE198907.

Human scRNAseq datasets were previously published (28). The processed dataset was downloaded from the GEO data repository under the accession number GSE142653. Cells were filtered and the dataset was scaled as previously described (28) and count thresholds were adjusted where necessary to account for background. The filtered and scaled gene expression dataset was analyzed using Seurat v.4.0.4 and standard procedures (29, 30). Cell types were assigned as previously published, and clustering was performed on the subset of endocrine cells (28).

## RNAscope mRNA in situ hybridisation

Wild type CD1 mice (MGI: 5649524) were purchased from Charles River Laboratories.

To analyse embryonic stages of pituitary gland development, females and males were timemated for the generation of embryos. Midday of the day of vaginal plug was considered

embryonic day 0.5 (E0.5). Adult pituitary glands were collected from 8-week-old CD-1 males. All animals were housed on a 12 h light: 12 h dark cycle and given access to food and water *ad libitum* under compliance of the Animals (Scientific Procedures) Act 1986 and KCL ethical review.

Dissected embryos and adult pituitaries were fixed in 10% neutral buffered formalin (NBF) at room temperature for 16-24 h. Samples were then washed in PBS and dehydrated through graded ethanol series before paraffin embedding as previously described (31). Embryo samples were sectioned along the sagittal plane for ages E9.5-16.5 and frontal plane for older embryos and adult pituitaries, at a thickness of  $5 \, \mu m$ .

The RNAscope 2.5 HD Duplex assay was used according to the manufacturer's recommendations, with a combination of the following probes; Mm-Tgfbr3l-C1 (Cat# 1040221-C1), Mm-Nr5a1-C2 (Cat# 445731-C2), Mm-Fshb-C2 (Cat# 445351-C2), Mm-Lhb-C2 (Cat# 478401-C2). All reagents were from Advanced Cell Diagnostics (Newark, CA, USA). All sections were counterstained with Mayer's hematoxylin (Vector H-3404) and mounted with Vectamount Permanent Mounting Medium (Vector H-5000).

For brightfield images, slides were scanned using an Olympus BX34F Brightfield microscope.

## Statistical analysis

Luciferase assays in HEK93T and LβT2 cells were analyzed by one-way or two-way ANOVA, followed by *post-hoc* Holm-Sidak multiple comparisons tests. Where indicated, effects of genotype between two groups were assessed by unpaired *t*-tests with Welch's correction. Statistical analyses were performed using Prism 9, GraphPad software. Alpha was set at p < 0.05.

#### Results

## Two SF-1 binding sites are located in the proximal *Tgfbr3l* promoter

We mapped the *Tgfbr3l* transcription start site (TSS, +1) in murine pituitary RNA using 5' rapid amplification of cDNA ends (5' RACE). Sequencing of several clones indicated that transcription was initiated at one of two sites: either 29 base pairs (at +1) or 52 base pairs (at -23) upstream of the start codon (Fig. 1A). The 29 base pair untranslated region (UTR) was more common (8 clones out of 11) and was therefore used to define the TSS. Both experimentally determined UTRs differed from the computationally predicted TSS (at -40) in GenBank (NM\_001195258.1). We then analysed the proximal promoter region for potential transcription factor binding sites and identified two candidate SF-1 *cis*-elements at -146 to -138 (CTGGCCTTG, site 1) and -67 to -59 (CAAGGCCAG, site 2). These two elements were reverse complements of each other and differed from the consensus SF-1 binding motif by one base pair (32, 33).

To assess SF-1 binding to these sequences, we performed DNA affinity purification assays (DNAP) using biotinylated double-stranded DNA probes corresponding to each candidate *cis*-element (Fig. 1B). To ascertain specific binding, we also used DNA probes with 2-bp mutations in the putative SF-1 *cis*-elements. Endogenous SF-1 protein from LβT2 cells bound to wild-type (Fig. 1B, lanes 2 and 4) but not mutant probes (lanes 3 and 5) corresponding to both *cis*-elements. Though the two *cis*-elements were identical (reverse complements of each other), site 1 appeared to bind SF-1 more strongly than site 2. Finally, we performed chromatin immunoprecipitation in LβT2 cells to assess SF-1 binding in the context of native chromatin. Compared to IgG, we observed enrichment of SF-1 in a region of the *Tgfbr3I* promoter containing the two cis-elements but not in a negative (gene desert) control (34) (Fig. 1C).

## SF-1 activates murine *Tgfbr3I* promoter-reporter activity

To examine Tgfbr3l transcription, we ligated ~1 kb of the murine Tgfbr3l 5' flanking sequence (-999/+1) upstream of luciferase in the pGL3-basic reporter plasmid. In heterologous HEK293T cells, ectopically expressed SF-1 activated Tgfbr3l reporter activity (Fig. 1D). Mutations in either or both SF-1 sites blunted or blocked this stimulatory effect. In homologous murine L $\beta$ T2 gonadotrope-like cells, mutations in the SF-1 binding sites significantly decreased basal reporter activity relative to wild-type (Fig. 1E). Reporter activity was also significantly attenuated following SF-1 knockdown in L $\beta$ T2 cells using a previously validated siRNA against Nr5a1 (Fig. 1F) (17).

## SF-1 also regulates human *TGFBR3L* promoter-reporter activity

The TSS of human *TGFBR3L* was previously determined (11). Alignment of the murine *Tgfbr3l* and human *TGFBR3L* promoters demonstrated a high degree of sequence conservation, including in the two SF-1 *cis*-elements (Fig. 1A). Using DNAP, we demonstrated SF-1 binding to both *cis*-elements in the human promoter (Fig. 2A, lanes 2 and 4). Mutations in critical bp in these sites blocked SF-1 binding (lanes 3 and 5). In HEK293T cells, SF-1 overexpression induced human *TGFBR3L* promoter-reporter activity (Fig. 2B). The mutations that blocked SF-1 binding (Fig. 2A) also abrogated SF-1 induction of reporter activity (Fig. 2B). In LβT2 cells, mutations in these *cis*-element also decreased basal promoter-reporter activity (Fig. 2C), as did siRNA-mediated knockdown of SF-1 (Fig. 2D).

## Tafbr3I expression is SF-1-dependent in vivo

To determine whether SF-1 regulates *Tgfbr3I* expression *in vivo*, we generated gonadotrope-specific *Nr5a1* knockout mice by crossing *Gnrhr*<sup>GRIC</sup> and *Nr5a1*<sup>fl/fl</sup> animals. Cre is expressed in gonadotropes and in the male germline with the GRIC Cre-driver line (19). We observed recombination of the floxed *Nr5a1* allele in pituitaries (both sexes, lanes 2 and 12) and

in testis (lane 14, Fig. 3A) (21). There was no evidence of recombination in control mice, which harbored floxed alleles but no Cre (Fig. 3A, lanes 6-9 and 16-19). Ablation of SF-1 protein (Fig. 3B) and *Nr5a1* mRNA expression (Fig. 3C) was demonstrated by immunofluorescence and RT-qPCR on pituitaries of conditional knockouts (*Nr5a1*<sup>fl/fl</sup>; *Gnrhr*<sup>GRIC/+</sup>, cKO) compared to controls

SF-1 is required for gonadotropin synthesis and fertility *in vivo* (20, 35). Here, we observed profound impairments in gonadotropin subunits (*Lhb* and *Fshb*) and *Gnrhr*, but not *Cga*, mRNA levels in pituitaries of female and male cKOs (Fig. 3C). Serum LH and FSH levels were correspondingly reduced in cKO mice (Fig. 3D). Both female and male cKOs were infertile, with severely hypoplastic gonads and accessory sex organs (ovaries and uteri in females; testes and seminal vesicles in males; Fig. 3E-F). Collectively, the data demonstrate that loss of SF-1 expression and function was complete in our model.

Consistent with the *in vitro* reporter data (Fig. 1), pituitary *Tgfbr3l* expression was abrogated in both female and male cKO mice (Fig. 4A). Next, we performed single-nucleus ATAC-sequencing on pituitaries of male control and cKO mice. In the controls, we identified open chromatin around the *Tgfbr3l* promoter in gonadotropes (upper track in Fig. 4B). In contrast, the corresponding region was closed in cKO mice (lower track). The *Cga* promoter was open in gonadotropes of both genotypes (Fig. 4C), consistent with their equivalent expression of the gene (Fig. 3C).

(*Nr5a1*<sup>fl/fl</sup>).

## Tafbr3I precedes Nr5a1 expression in the embryonic murine pituitary

Next, we examined *Tgfbr3I* expression during murine pituitary development. Using mRNA *in situ* hybridization (RNAscope) on CD1 mouse embryos, we observed a low level of *Tgfbr3I* expression as early as E13.5 (Fig. 5A). In contrast, *Nr5a1* mRNA was first detected at E15.5 (Fig. 5A). *Tgfbr3I* co-localized with *Nr5a1* (Fig. 5A) and *Lhb* by E18.5 (Fig. 5B). *Tgfbr3I* 

- co-localization with *Fshb* was not complete at E18.5 (Fig. 5C). In adult (8-week-old) males, *Tgfbr3l* co-localized with *Nr5a1* (Fig. 5D), *Fshb* (Fig. 5E), and *Lhb* (Fig. 5F).
  - Finally, to gain insight into TGFBR3L regulation in human development, we analyzed a human embryonic pituitary single-cell RNA sequencing database (28) (Fig. 6A). *TGFBR3L* and *NR5A1* expression were enriched in gonadotropes 7-25 weeks post-fertilization (Fig. 6B and C).

Discussion

The novel inhibin B co-receptor, TGFBR3L, appears to be uniquely or principally expressed in pituitary gonadotropes (11, 13-15). Here, we demonstrate that the gonadotrope-specific transcription factor SF-1 regulates murine *Tgfbr3l* expression, at least in part, via two cis-elements in the proximal promoter. The data also suggest that this mechanism is conserved in humans. Beyond binding to these elements, how SF-1 regulates *Tgfbr3l* is not yet clear. However, the closed chromatin state of the *Tgfbr3l* locus in gonadotropes of conditional knockout (cKO) mice suggests that SF-1 promotes chromatin accessibility through the recruitment of histone modifying enzymes (36-38).

Whereas SF-1 is necessary for *Tgfbr3l* expression, it is likely not sufficient. Though restricted to gonadotropes among pituitary cell types, SF-1 is expressed in other tissues that do not express *Tgfbr3l* (11), including the ventromedial hypothalamus, adrenal glands, and gonads (39). Within gonadotropes, SF-1 physically and functionally interacts with early growth response 1 (EGR1) and *paired*-like homeodomain transcription factors to regulate gonadotrope-specific expression of *Lhb* (17). In contrast, SF-1 cooperates with LIM homeodomain proteins to regulate *Gnrhr* promoter activity (40). It is possible that SF-1 might interact with similar or distinct transcription factors to confer gonadotrope-specific *Tgfbr3l* expression. Notably, there is a candidate EGR1 binding site between the two SF-1 *cis*-elements in the *Tgfbr3l* promoter, which is the subject of our ongoing investigations.

Importantly, the dependence of *Tgfbr3l* expression on SF-1 may be an emergent property. *Nr5a1* mRNA is reliably detected in developing murine pituitary on embryonic day 14.5, but not at E13.5 (35). Using RNAscope, *Tgfbr3l* mRNA was first detected at E13.5, when *Nr5a1* mRNA was absent. These data indicate that the initial expression of *Tgfbr3l* is SF-1 independent. Nevertheless, *Nr5a1* and *Tgfbr3l* are co-expressed at least as early as E15.5 and continue to be thereafter. The loss of *Tgfbr3l* mRNA in *Nr5a1* cKO mice demonstrates that, at least postnatally, the gene is uniquely/preferentially expressed in gonadotropes in an SF-1 dependent manner. Though we have not yet established what initially drives *Tgfbr3l* expression, this mechanism does not compensate for the loss of SF-1 in adulthood.

*NR5A1* and *TGFBR3L* are also co-expressed in human embryonic pituitary development. However, based on the available data, we cannot determine precisely when these transcripts first emerge relative to one another. Regardless, as in mouse, SF-1 and TGFBR3L are co-expressed in adult human gonadotropes, as well as in gonadotrope tumors (14, 28).

Gnrhr and the gonadotropin β subunits (*Lhb* and *Fshb*) are canonical markers of the gonadotrope lineage. The expression of all three depends on SF-1 (35). Recent single-cell and single-nucleus RNA-sequencing analyses of murine, rat, and human pituitaries similarly establish *Tgfbr3l/TGFBR3L* as another gonadotrope-specific gene (13, 41, 42)}. It is therefore notable that its expression is also SF-1 dependent. These data demonstrate SF-1's role as a master regulator of gonadotrope identity. Nevertheless, as the expression of two of these genes, *Gnrhr* (21) and *Tgfbr3l*, precedes *Nr5a1* developmentally, gonadotrope-lineage specification appears to be SF-1 independent. Indeed, treatment of *Nr5a1* knockout mice with exogenous GnRH is sufficient to increase gonadotropin production (43), indicating that gonadotropes are present even in the absence of SF-1. It will be interesting to determine whether GnRH treatment similarly induces *Tgfbr3l*. Collectively, the data indicate that SF-1 is required for the full expression of the gonadotrope-specific transcriptome, but is not required for gonadotrope specification per se.

Finally, we should note that deciphering mechanisms controlling *Tgfbr3l/TGFBR3L* expression may have translational relevance. Female *Tgfbr3l* knockout mice have elevated FSH levels and enhanced fertility due to impaired inhibin B negative feedback (11). Therefore, either blocking inhibin B binding to TGFBR3L or reducing TGFBR3L expression would provide means to increase endogenous FSH levels. Such an outcome could be favorable in the context of assisted reproduction. Though SF-1 itself may not be an ideal therapeutic target, delineation of the *Tgfbr3l/TGFBR3L* transcriptional regulatory machinery may uncover a more suitable and selective approach to decrease gene expression. The results reported here provide an important first step in this direction.

#### **Data Availability Statement**

Most data are available in the manuscript. ATAC-seq data were deposited in GEO: GSE198907

## **Author Contributions**

YFL and DJB were responsible for the experimental design, data analyses, and manuscript preparation. YFL and ERSB conducted the *in vitro* experiments. GS, HS, and YFL were responsible for tissue collection, mouse colony management, and analyses from the SF-1 strain. TLW performed the RNAscope. UB provided the GRIC strain. NM isolated nuclei from individual pituitaries. FRZ performed the snATAC-seq experiments and MZ analyzed the snATAC-seq datasets. HS analyzed the human scRNA-seq datasets. DJB, CLA, and SCS secured the grant funding for the research. All authors approved the final version of the manuscript.

## Acknowledgements

The thank the following individuals: Dr. Bruce Murphy (Université de Montréal) for floxed SF-1 mice; Drs. Terry Hébert (HEK293T; McGill University) and Pamela Mellon (LβT2; UCSD) for

immortalized cell lines; Dr. Keith Parker (UT Southwestern Medical Center) for the SF-1

expression vector; and Dr. Caroline David for feedback on the manuscript. We acknowledge the

3 New York Genome Center for sequencing. This work was supported in part through the

computational and data resources and staff expertise provided by Scientific Computing at the

Icahn School of Medicine at Mount Sinai.

2

4

5

#### References

- 2 1. Edson, M. A., Nagaraja, A. K., and Matzuk, M. M. (2009) The mammalian ovary from
- genesis to revelation. *Endocr Rev* **30**, 624-712
- 4 2. Simoni, M., Weinbauer, G. F., Gromoll, J., and Nieschlag, E. (1999) Role of FSH in male
- 5 gonadal function. *Ann Endocrinol (Paris)* **60**, 102-106
- 6 3. Fortin, J., Ongaro, L., Li, Y., Tran, S., Lamba, P., Wang, Y., Zhou, X., and Bernard, D. J.
- 7 (2015) Minireview: Activin Signaling in Gonadotropes: What Does the FOX say... to the
- 8 SMAD? Molecular Endocrinology **29**, 963-977
- 9 4. Woodruff, T. K., D'Agostino, J., Schwartz, N. B., and Mayo, K. E. (1988) Dynamic
- 10 changes in inhibin messenger RNAs in rat ovarian follicles during the reproductive cycle.
- 11 Science **239**, 1296-1299
- 12 5. Woodruff, T. K., Meunier, H., Jones, P. B., Hsueh, A. J., and Mayo, K. E. (1987) Rat
- inhibin: molecular cloning of alpha- and beta-subunit complementary deoxyribonucleic
- acids and expression in the ovary. *Mol Endocrinol* **1**, 561-568
- 15 6. Davis, S. R., Krozowski, Z., McLachlan, R. I., and Burger, H. G. (1987) Inhibin gene
- expression in the human corpus luteum. *J Endocrinol* **115**, R21-23
- 17 7. Anawalt, B. D., Bebb, R. A., Matsumoto, A. M., Groome, N. P., Illingworth, P. J.,
- 18 McNeilly, A. S., and Bremner, W. J. (1996) Serum inhibin B levels reflect Sertoli cell
- function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 81,
- 20 3341-3345
- 21 8. Lewis, K. A., Gray, P. C., Blount, A. L., MacConell, L. A., Wiater, E., Bilezikjian, L. M.,
- and Vale, W. (2000) Betaglycan binds inhibin and can mediate functional antagonism of
- activin signalling. *Nature* **404**, 411-414
- 9. Makanji, Y., Temple-Smith, P. D., Walton, K. L., Harrison, C. A., and Robertson, D. M.
- 25 (2009) Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone
- 26 Release than Inhibin A in Vitro and in Vivo. *Endocrinology* **150**, 4784-4793

- 1 10. Li, Y., Fortin, J., Ongaro, L., Zhou, X., Boehm, U., Schneyer, A., Bernard, D. J., and Lin,
- 2 H. Y. (2018) Betaglycan (TGFBR3) Functions as an Inhibin A, but Not Inhibin B,
- Coreceptor in Pituitary Gonadotrope Cells in Mice. *Endocrinology* **159**, 4077-4091
- 4 11. Brule, E., Wang, Y., Li, Y., Lin, Y. F., Zhou, X., Ongaro, L., Alonso, C. A. I., Buddle, E. R.
- 5 S., Schneyer, A. L., Byeon, C. H., Hinck, C. S., Mendelev, N., Russell, J. P., Cowan, M.,
- Boehm, U., Ruf-Zamojski, F., Zamojski, M., Andoniadou, C. L., Sealfon, S. C., Harrison,
- 7 C. A., Walton, K. L., Hinck, A. P., and Bernard, D. J. (2021) TGFBR3L is an inhibin B co-
- 8 receptor that regulates female fertility. Sci Adv 7, eabl4391
- 9 12. Bilandzic, M., and Stenvers, K. L. (2011) Betaglycan: a multifunctional accessory. *Mol*
- 10 *Cell Endocrinol* **339**, 180-189
- 13. Ruf-Zamojski, F., Zhang, Z., Zamojski, M., Smith, G. R., Mendelev, N., Liu, H.,
- Nudelman, G., Moriwaki, M., Pincas, H., Castanon, R. G., Nair, V. D., Seenarine, N.,
- Amper, M. A. S., Zhou, X., Ongaro, L., Toufaily, C., Schang, G., Nery, J. R., Bartlett, A.,
- Aldridge, A., Jain, N., Childs, G. V., Troyanskaya, O. G., Ecker, J. R., Turgeon, J. L.,
- Welt, C. K., Bernard, D. J., and Sealfon, S. C. (2021) Single nucleus multi-omics
- regulatory landscape of the murine pituitary. *Nat Commun* **12**, 2677
- 17 14. Sjostedt, E., Kolnes, A. J., Olarescu, N. C., Mitsios, N., Hikmet, F., Sivertsson, A.,
- Lindskog, C., Oystese, K. A. B., Jorgensen, A. P., Bollerslev, J., and Casar-Borota, O.
- 19 (2020) TGFBR3L-An Uncharacterised Pituitary Specific Membrane Protein Detected in
- the Gonadotroph Cells in Non-Neoplastic and Tumour Tissue. Cancers (Basel) 13
- 21 15. The Human Protein Atlas.
- 22 16. Wang, Y., Fortin, J., Lamba, P., Bonomi, M., Persani, L., Roberson, M. S., and Bernard,
- D. J. (2008) Activator protein-1 and smad proteins synergistically regulate human follicle-
- stimulating hormone beta-promoter activity. *Endocrinology* **149**, 5577-5591

- 1 17. Fortin, J., Lamba, P., Wang, Y., and Bernard, D. J. (2009) Conservation of mechanisms
- 2 mediating gonadotrophin-releasing hormone 1 stimulation of human luteinizing hormone
- beta subunit transcription. *Mol Hum Reprod* **15**, 77-87
- 4 18. Alarid, E. T., Windle, J. J., Whyte, D. B., and Mellon, P. L. (1996) Immortalization of
- 5 pituitary cells at discrete stages of development by directed oncogenesis in transgenic
- 6 mice. *Development* **122**, 3319-3329
- 7 19. Wen, S., Schwarz, J. R., Niculescu, D., Dinu, C., Bauer, C. K., Hirdes, W., and Boehm,
- 8 U. (2008) Functional characterization of genetically labeled gonadotropes.
- 9 *Endocrinology* **149**, 2701-2711
- 20. Zhao, L., Bakke, M., Krimkevich, Y., Cushman, L. J., Parlow, A. F., Camper, S. A., and
- Parker, K. L. (2001) Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope
- 12 function. *Development* **128**, 147-154
- 13 21. Wen, S., Ai, W., Alim, Z., and Boehm, U. (2010) Embryonic gonadotropin-releasing
- hormone signaling is necessary for maturation of the male reproductive axis. *Proc Natl*
- 15 Acad Sci U S A **107**, 16372-16377
- 16 22. Luo, X., Ikeda, Y., and Parker, K. L. (1994) A cell-specific nuclear receptor is essential
- for adrenal and gonadal development and sexual differentiation. *Cell* 77, 481-490
- 18 23. Zhou, X., Wang, Y., Ongaro, L., Boehm, U., Kaartinen, V., Mishina, Y., and Bernard, D.
- J. (2016) Normal gonadotropin production and fertility in gonadotrope-specific Bmpr1a
- 20 knockout mice. *J Endocrinol* **229**, 331-341
- 21 24. Steyn, F. J., Wan, Y., Clarkson, J., Veldhuis, J. D., Herbison, A. E., and Chen, C. (2013)
- 22 Development of a methodology for and assessment of pulsatile luteinizing hormone
- secretion in juvenile and adult male mice. *Endocrinology* **154**, 4939-4945
- 24 25. Schang, G., Ongaro, L., Schultz, H., Wang, Y., Zhou, X., Brule, E., Boehm, U., Lee, S.
- 25 J., and Bernard, D. J. (2020) Murine FSH Production Depends on the Activin Type II
- 26 Receptors ACVR2A and ACVR2B. Endocrinology 161

- 1 26. Stuart, T., Srivastava, A., Madad, S., Lareau, C. A., and Satija, R. (2021) Single-cell
- chromatin state analysis with Signac. *Nat Methods* **18**, 1333-1341
- 3 27. Thorvaldsdottir, H., Robinson, J. T., and Mesirov, J. P. (2013) Integrative Genomics
- 4 Viewer (IGV): high-performance genomics data visualization and exploration. *Brief*
- 5 *Bioinform* **14**, 178-192
- 6 28. Zhang, S., Cui, Y., Ma, X., Yong, J., Yan, L., Yang, M., Ren, J., Tang, F., Wen, L., and
- 7 Qiao, J. (2020) Single-cell transcriptomics identifies divergent developmental lineage
- 8 trajectories during human pituitary development. *Nat Commun* **11**, 5275
- 9 29. Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018) Integrating
- single-cell transcriptomic data across different conditions, technologies, and species. *Nat*
- 11 Biotechnol **36**, 411-420
- 30. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., 3rd,
- Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019) Comprehensive Integration of
- 14 Single-Cell Data. Cell 177, 1888-1902 e1821
- 15 31. Russell, J. P., Lim, X., Santambrogio, A., Yianni, V., Kemkem, Y., Wang, B., Fish, M.,
- Haston, S., Grabek, A., Hallang, S., Lodge, E. J., Patist, A. L., Schedl, A., Mollard, P.,
- Nusse, R., and Andoniadou, C. L. (2021) Pituitary stem cells produce paracrine WNT
- signals to control the expansion of their descendant progenitor cells. *Elife* **10**
- 19 32. Doghman, M., Figueiredo, B. C., Volante, M., Papotti, M., and Lalli, E. (2013) Integrative
- 20 analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene
- expression regulation. *Nucleic Acids Res* **41**, 8896-8907
- 22 33. Keri, R. A., and Nilson, J. H. (1996) A steroidogenic factor-1 binding site is required for
- activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic
- 24 mice. *J Biol Chem* **271**, 10782-10785

- 1 34. Bohaczuk, S. C., Thackray, V. G., Shen, J., Skowronska-Krawczyk, D., and Mellon, P. L.
- 2 (2021) FSHB Transcription is Regulated by a Novel 5' Distal Enhancer With a Fertility-
- 3 Associated Single Nucleotide Polymorphism. Endocrinology 162
- 4 35. Ingraham, H. A., Lala, D. S., Ikeda, Y., Luo, X., Shen, W. H., Nachtigal, M. W., Abbud,
- 5 R., Nilson, J. H., and Parker, K. L. (1994) The nuclear receptor steroidogenic factor 1
- acts at multiple levels of the reproductive axis. Genes Dev 8, 2302-2312
- 7 36. Harris, J., Gouhier, A., and Drouin, J. (2021) MECHANISMS IN ENDOCRINOLOGY:
- 8 Pioneer transcription factors in pituitary development and tumorigenesis. *Eur J*
- 9 *Endocrinol* **184**, R1-R15
- 10 37. Mayran, A., Sochodolsky, K., Khetchoumian, K., Harris, J., Gauthier, Y., Bemmo, A.,
- Balsalobre, A., and Drouin, J. (2019) Pioneer and nonpioneer factor cooperation drives
- lineage specific chromatin opening. *Nat Commun* **10**, 3807
- 13 38. Zaret, K. S., and Carroll, J. S. (2011) Pioneer transcription factors: establishing
- competence for gene expression. Genes Dev 25, 2227-2241
- 39. Schimmer, B. P., and White, P. C. (2010) Minireview: steroidogenic factor 1: its roles in
- differentiation, development, and disease. *Mol Endocrinol* **24**, 1322-1337
- 17 40. Granger, A., Bleux, C., Kottler, M. L., Rhodes, S. J., Counis, R., and Laverriere, J. N.
- 18 (2006) The LIM-homeodomain proteins Isl-1 and Lhx3 act with steroidogenic factor 1 to
- enhance gonadotrope-specific activity of the gonadotropin-releasing hormone receptor
- gene promoter. Mol Endocrinol 20, 2093-2108
- 41. Fletcher, P. A., Smiljanic, K., Maso Prévide, R., Iben, J. R., Li, T., Rokic, M. B.,
- Sherman, A., Coon, S. L., and Stojilkovic, S. S. (2019) Cell Type- and Sex-Dependent
- Transcriptome Profiles of Rat Anterior Pituitary Cells. Frontiers in Endocrinology 10
- 24 42. Zhang, Z., Zamojski, M., Smith, G. R., Willis, T. L., Yianni, V., Mendelev, N., Pincas, H.,
- Seenarine, N., Amper, M. A. S., Vasoya, M., Cheng, W. S., Zaslavsky, E., Nair, V. D.,
- Turgeon, J. L., Bernard, D. J., Troyanskaya, O. G., Andoniadou, C. L., Sealfon, S. C.,

- and Ruf-Zamojski, F. (2022) Single nucleus transcriptome and chromatin accessibility of postmortem human pituitaries reveal diverse stem cell regulatory mechanisms. *Cell Rep* 38, 110467

  Ikeda, Y., Luo, X., Abbud, R., Nilson, J. H., and Parker, K. L. (1995) The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial
- 6 hypothalamic nucleus. *Mol Endocrinol* **9**, 478-486

## **Figure Legends**

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1

Figure 1. SF-1 activates murine Tgfbr3l transcription via two cis-elements in the proximal promoter. (A) Alignment of the murine and human Tgfbr3l/TGFBR3L promoters. In both cases, +1 refers to the transcription start site. The most common murine 5' untranslated region (5' UTR, +1/+29) is boxed in blue and the human 5' UTR is boxed in green. The conserved SF-1 binding sites are boxed in red and labeled as site 1 and site 2. Mutated base pairs (in B, C, and D) are indicated above in green. (B) DNAP using probes corresponding to the wild-type and mutant murine SF-1 *cis*-elements. Whole cell protein lysates from LβT2 cells (input) or proteins interacting with the probes were analyzed via immunoblot (IB) using an SF-1 antibody. (C) Chromatin immunoprecipitation for SF-1 of the indicated genomic regions in L\u00e3T2 cells (n=4). (D) HEK293T cells were transfected with 225 ng/well of the indicated murine -999/+1 Tgfbr3I-luc reporters as well as 3.125 ng/well of either pcDNA3.0 (empty expression vector) or SF-1 expression vector. WT, wild-type; site 1 mut, mutated SF-1 site 1; site 2 mut, mutated SF-1 site 2; double mut, both SF-1 sites mutated. (E) LBT2 cells were transfected with 225 ng/well of the indicated promoter-reporters. (F) LBT2 cells were transfected with 225 ng/well of the -999/+1 Tafbfr3I-luc reporter and 10 nM of control or Nr5a1 siRNA. In D-F, lysates were collected and reporter activity measured by luciferase assay. Data represent the mean of three or more independent experiments performed in triplicate. Data were analyzed by two-way ANOVA followed by Holm-Sidak multiple comparisons test in (D), one-way ANOVA followed by Dunnett's multiple comparisons test in (E), and two-tailed unpaired t test with Welch's correction in (C and F). ns, not significant; \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001; \*\*\*\*, p<0.0001.

23

24

25

26

Figure 2. Mechanisms of human *TGFBR3L* transcriptional regulation by SF-1 are conserved. (A) DNAP was performed as in Fig. 1B, but with probes corresponding to the wild-type and mutant human SF-1 *cis*-elements. (B) HEK293T cells were transfected with 225

ng/well of the indicated human -996/+1 *TGFBR3L*-luc reporters as well as 3.125 ng/ well of either pcDNA3.0 (empty expression vector) or SF-1 expression vector. WT, wild-type; site 1 mut, mutated SF-1 site 1; site 2 mut, mutated SF-1 site 2; double mut, both sites mutated. (C) LβT2 cells were transfected with 225 ng/well of the indicated promoter-reporters. (D) LβT2 cells were transfected with 225 ng/well of the -996/+1 *TGFBR3L*-luc reporter and 10 nM of control or *Nr5a1* siRNA. In B-D, luciferase assays were performed as in Fig. 1. Data represent the mean of three independent experiments performed in triplicate and were analyzed by two-way ANOVA followed by Holm-Sidak multiple comparisons test (B), one-way ANOVA followed by Dunnett's multiple comparisons test (C), or by a two-tailed unpaired t test with Welch's correction (D). ns, not significant; \*, p<0.05; \*\*, p<0.01; \*\*\*\*, p<0.001; \*\*\*\*\*, p<0.0001.

Figure 3. Gonadotrope-specific SF-1 knockout mice exhibit hypogonadotropic was extracted from hypogonadism. (A) Genomic DNA the indicated tissues of Nr5a1<sup>fl/fl</sup>; Gnrhr<sup>GRIC/+</sup> (cKO; left panels) and Nr5a1<sup>fl/fl</sup> (control; right panels) mice and analyzed by PCR for the presence of the floxed or recombined (rec) Nr5a1 alleles. (B) Pituitary sections from 11-week-old control and cKO mice were analyzed for SF-1 by immunofluorescence (red); DAPI (blue) was used to stain nuclei. Scale bars: 50 µm. (C) cDNA was prepared from total RNA isolated from individual pituitary glands of 8-10-week-old control and cKO female (top) and male (bottom) mice and analyzed by RT-qPCR for expression of Lhb, Fshb, Cga, Gnrhr, and Nr5a1. (D) Serum LH and FSH levels in female (top) and male (bottom) control and cKO mice. (E) Ovarian, uterine, testicular, and seminal vesicle weights and (F) representative images of gonads and accessory sex organs from control and cKO females (top) and males (bottom). Scale bars: 5 mm. Female data in all panels represent randomly cycling females. Data were analyzed by two-tailed unpaired t tests with Welch's correlation. ns, not significant; \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001; \*\*\*\*, p<0.0001.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Figure 4. SF-1 is required for *Tgfbr3I* expression in adult murine pituitary glands. (A)
- 2 Pituitary cDNA from control and cKO female and male mice (described in Fig. 3) were analyzed
- for Tafbr3I expression by RT-qPCR. Data were analyzed by two-tailed unpaired t tests with
- 4 Welch's correlation. \*\*\*, p<0.001. Chromatin accessibility, as measured with single-nucleus
- 5 ATAC-seq, over the (B) Tgfbr3l and (C) Cga genes in gonadotropes of 10-12-week-old control
- 6 (orange) and cKO (grey) males. Exon 1 and the promoter of *Tafbr3I* are boxed in red in panel B.
- 7 Shown are representative tracks from a control and a cKO animal.

8

- 9 Figure 5. Nr5a1 and Tgfbr3l expression in fetal and adult murine pituitaries. (A) mRNA in
- situ hybridization (RNAscope) for Tgfbr3l (blue) and Nr5a1 (red) on heads of wild-type CD1
- embryos at the indicated ages. Boxed regions in the top panels are magnified in the bottom
- panels. Scale bars: 50 μm. Duplex RNAscope for *Tgfbr3I* (blue) and (B) *Lhb* or (C) *Fshb* (red)
- on heads of CD1 embryos at E18.5. Scale bars: 200 μm (top) and 50 μm (bottom).. Duplex
- RNAscope for Tgfbr3l (blue) and (D) Nr5a1, (E) Fshb, or (F) Lhb (red) on pituitaries of 8-week-
- old CD1 males. Scale bars: 50 µm.

16

- 17 Figure 6. TGFBR3L and NR5A1 expression is enriched in gonadotropes of human fetal
- pituitaries. (A) UMAP plots of scRNAseq of 21 human embryonic pituitaries collected 7-25
- 19 weeks post-fertilization. Different colored clusters represent different pituitary cell types. (B)
- 20 Feature plots of TGFBR3L and NR5A1 expression. (C) Violin plots of TGFBR3L and NR5A1
- 21 expression in the defined cell lineages.


## **Table 1: Primers**

Tgfbr3/SF-1 site 1 mut R  GCCCTTATCCATGGCTGGAATTGAGCATGTGCTCAGAT Tgfbr3/SF-1 site 2 mut F  GGTGGCAGCCTCACCAATTCCAGGGCTACC Tgfbr3/SF-1 site 2 mut R  GGTAGCCCTGGAATTGGTGAGGCTGCCACC TGFBR3L SF-1 site 1 mut F  CCCAGAGCCAATGCCCAATTCCTGAGGGATTAAGGG TGFBR3L SF-1 site 1 mut R  CCCTTAATCCCCTCAGGAATTGGCCATTGGCTCTGG TGFBR3L SF-1 site 1 mut R  CCCTTAATCCCCTCAGGAATTGGGCATTGGCTCTGG TGFBR3L SF-1 site 2 mut F  GGCGGCCCTGTAATTGGCAAGGAGGGAGGCA TGFBR3L SF-1 site 2 mut R  TGCCTCCCTCCTTGCCAATTACAGGGCCC  qPCR primers  Fshb F  GTGCGGGCTACTGCTACACT Fshb R  CAGGCAATCTTACGGTCTCG Gnrhr F  TTGGCTACCTCCTTTGTCGT  Gnrhr R  CACGGGTTTAGGAAAGCAAA  Lhb F  ACTGTGCCGGCCTGTCAACG  Lhb R  ACTGTGCCGGCCTGTCAACG  Lhb R  AGCAGCCGGCAGTACTCCTAACG  Nr5a1 F  ACAAGGTTAATCCAACAGGGCAG  Rpl19 F  CGGGAATCCTACAGTTCCT  TGfbr3/I R  CCGGAATCCAAGAAGATTGA  TTCAGCTTGTGGAATTCCAACT  Tgfbr3/I SF-1 ChIP qPCR F  TCAGGTACACCAGTGCCTTTGA  Tgfbr3/I SF-1 ChIP qPCR R  GTACCCAGCCCTCTAGGT  Gene desert qPCR R  GGACATGTTCAGGAACCAAGGCC  GRIC F  GGACATGTTCAGGAACCAGGC  GRIC F  GGACATGTTCAGGAACCATGTGA  Rpl19 R  GTACCCAGCCCTCTAGGT  Gene desert qPCR R  GTACCCAGCACCATGTGATTACG  GGACATGTTCAGGAAACGCAAAGGTTTA  GGACTTCCAGGAACCAGTGCCTTTGA  GGACATCCAAGAAACGCCAAAGGTTTA  GGACATCCAAGAAACGCCAAAGGTTTA  GGACATCCAAGAAACGCCAAAGGTTTA  GGACATCCAAGAAACGCCAAGGTTTA  GGACATCCAAGAAACGCCAAAGGTTTA  GGACATCCAAGAAACGCAAAGGTTTA  GGACATCTCAAGGAAACGCAAAGGTTTA  GGACATCTCAAGGAAACGCAAAGGTTTA  GGACATCTCAAGGAAACGCAAAGGTTTA  GGACATCTCAAGGAAACGCAAAGGTTTA  GGACACCAGTGCCTCTAAGG  GGACATGTTCAGGGATCGCCAGGC  GRIC R  GACAAGGTTCATCAAGAAACACACATTGCTG  Nr5a1 R  ACAAGGTTCATCAACAAGAACACACATTGCTC  Nr5a1 R  ACAAGGTTCATCAACAAGAACACACATTGCTC  Nr5a1 R  ACAAGGTTCATCAACAAGAGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCAAGGTTAC  ACAAGGTTCATCAACAACAAGGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCCAAGGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCCAAGGTTCC  Nr5a1 R  ACAAGGTTCATCAACAACAAGGCCAAGGCCAAGGTTCC  ACAAGGTTCAACAACAAGACACAAGGCAAGG	Musica Tothy 21 promotor amplification		
primer 5 RACE gene-specific outer R 5 RACE gene-specific inner R GGGCGTGAAGAAGAGTGTTAC -999/+1 promoter amplification R -999/+1 promoter amplification R Human Tgfbr3l promoter amplification R Human Tgfbr3l promoter amplification R Human Tgfbr3l promoter amplification AAAAACTCGAGTAGCAGCAGCACCTTC F -996/+1 promoter amplification R R Tgfbr3l/TGFBR3L mutagenesis Tgfbr3l/SF-1 site 1 mut F ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGC Tgfbr3l/SF-1 site 1 mut R GCCCTTATCCATGGCTGAATTGCAGCCATGGATAAGGGC Tgfbr3l/SF-1 site 2 mut F GGTGGCAGCCTCACCAATTCCAGCGCTACCACC Tgfbr3l/SF-1 site 1 mut F GGTAGCCCTGGAATTGGTGAGGCTGCACC Tgfbr3l/SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGGCAATGGCTCAGC TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGGCAATGGCTCAGC TGFBR3L SF-1 site 2 mut R GGCGGCCCTAATCCTGAGGGGATTAAGGG TGFBR3L SF-1 site 2 mut R GCCGGCCCTAATCCTGAGGGGATTAAGGG TGFBR3L SF-1 site 2 mut R GCCGGCCCTAATTCCTAGGGGATTAAGGG TGFBR3L SF-1 site 2 mut R GCCGGCCCTAATTCCTAGGGGATTAAGGG TGFBR3L SF-1 site 2 mut R GCCGGCCCTGAATTCCTAGAGGAATGGCCTCCGC TGFBR3L SF-1 site 2 mut R GCCGGCCCTGAATTCCTAGAGGAAGAGAGAGAGAGAA TGFBR3L SF-1 site 2 mut R GCCGGCCCTGTAATTCGCAAGAAGAGGAGCAA TGFBR3L SF-1 site 2 mut R GCCGGCCCTGTCACAATACCACT TGFBR3L SF-1 site 2 mut R GCCGGCCCTGTCCTTCCAACTACACT TGFBR3L SF-1 site 2 mut R GCCGGCCCTGTCCACCACTACCACACACACACACACACAC			
S'RACE gene-specific outer R 5'RACE gene-specific inner R 939/+1 promoter amplification F-999/+1 promoter amplification R Human Tgfbr3/ promoter amplification R AAAACTCGAGTAGCCGCAGCCCTCCC R Tgfbr3/ SF-1 site 1 mut F		GGACGGACGAGGTATTGTGA	
5' RACE gene-specific inner R -999/+1 promoter amplification R -999/+1 promoter amplification R -999/+1 promoter amplification R -996/+1 promoter amplification -996/+1 promoter amplification -996/+1 promoter amplification R -8404CGGGCTGAGCCCCCAGGCCAGGCCCCCCCCCCCCCCCCC		00700070000747704470	
-999/+1 promoter amplification F -999/+1 promoter amplification AAAAACTCGAGGTAGCGAGCACCT R Human Tgfbr3/ promoter amplification -996/+1 promoter amplification -996/+1 promoter amplification R TTTAAGCTGGAGTAGCATCCCTCTC F -996/+1 promoter amplification R TTTAAGCTTGACCAGCTGAGGTCGGA R Tgfbr3/TGFBR3L mutagenesis Tgfbr3/ SF-1 site 1 mut F ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGC Tgfbr3/ SF-1 site 1 mut R GCCCTTATCCATGGCTGAATTGCAGCACTGGATAAGGGC Tgfbr3/ SF-1 site 1 mut F GGTGGCAGCCTCACCAATTCCAGCCATGGCTCAGAT Tgfbr3/ SF-1 site 1 mut F GGTGGCAGCCTGACAATTCCAGGCATGCCACC Tgfbr3/ SF-1 site 1 mut F GGTGGCAGCCTGACAATTCCAGGGCTACC Tgfbr3/ SF-1 site 1 mut F GGTGGCAGCCTGAATTGGTGAGGCTTCC Tgfbr3/ SF-1 site 1 mut F GGTGGCAGCCAATTCCAGGAGTTGGCTCAGGA TGFBR3L SF-1 site 1 mut F GGTGGCAGCCAATTCCAGGAGTTGGCCACC TGFBR3/ SF-1 site 2 mut F GGCGGCCCTGTAATTGGCAATGGCCATGG TGFBR3/ SF-1 site 2 mut R GCCTTAATCCCTCAGGAATTGGCCATGGCCTCGG TGFBR3/ SF-1 site 2 mut R GCCTCCCTCCTTGCCAATTCAGGAGGAGGCA TGFBR3/ SF-1 site 2 mut R GCCGCCCTGTAATTGGCCATGGCCACC  TGFBR3/ SF-1 site 2 mut R GCCTCCCTCCTTGCCAATTACAGGGCCACC  TGFBR3/ SF-1 site 2 mut R GCCGCCCTGTAATTGGCAATGGCCATGCCTGG TGFBR3/ SF-1 site 2 mut R GCCTCCCTCCTTTGCCAATTACAGGGCCACC  TGFBR3/ SF-1 site 2 mut R GCCCCTCCTTTGCCAATTACAGGCCACC  TGFBR3/ SF-1 site 2 mut R GCCGGCCCTGTAATTGGCAATGGCCACC  TGFBR3/ SF-1 site 2 mut R GCCCTTACACC  TGCAGCAACCACTGCAACACACC  TGFBR3/ SF-1 site 2 mut R GCCCTTAGGTCTCG  TTCGCAACCACTGCTACACT  TTCGCTACCTTTTGTCCT  TTCGCAACCACACACCACCACCACCACCACCACCACCACCAC			
F -999/+1 promoter amplification R Human Tgfbr3/ promoter amplification -996/+1 promoter amplification R -996/+1 promoter amplification R Tgfbr3/TGFBR3L mutagenesis Tgfbr3/SF-1 site 1 mut F Tgfbr3/SF-1 site 2 mut F GCCCTTATCCATGGCTGAATTCCAGCCATGGATAAGGGC Tgfbr3/SF-1 site 2 mut F GGTAGCCCTGAATTCCAGGGTAGCATCCCTCAGT Tgfbr3/SF-1 site 2 mut F GGTAGCCCTGAATTCCAGGGCTACC Tgfbr3/SF-1 site 2 mut F GGTAGCCCTGAATTCCAGGGCTACC Tgfbr3/SF-1 site 2 mut F GCTGCAGCCTGCAATTCCAGGGCTACC Tgfbr3/SF-1 site 2 mut F GCTAGCCCTGGAATTCCTGAGGGCTACC Tgfbr3/SF-1 site 2 mut F GCTAGCCCTGAATTCCTGAGGGCTACC Tgfbr3/SF-1 site 1 mut R CCCTTAATCCCTCAGGAATTGAGGCACCAC TGFBR3L SF-1 site 1 mut R CCCTTAATCCCTCAGGAATTGAGGAATTAAGGG TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGAGGAATTAAGGG TGFBR3L SF-1 site 2 mut R GCCGGCCCTGTAATTGGCAAGGAGGGAGCA TGFBR3L SF-1 site 2 mut R TGCCTCCCTCTTGCCAATTACAGGGCCCC  QPCR primers Fshb F GTGCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCCA Gnrhr F TTCGCTACCTCCTTTGTCGT Gnrhr R CAGGCAATCTTACGGTCTCG Gnrhr R CAGGCAATCTTACGGTCTCAACG Lhb F ACTGTGCCGGCCTGTCAACG Lhb R ACAGGTTAACGACACAC Lhb R ACAGGCGAATACTCCACACG Lhb R ACAGGTTAACGACACACACAC Lhb R ACAGGTTAATCCAACAGGCAA  Nr5a1 F ACAAGGTTAATCCAACAGGCAG Rpl19 R TCAGCTTGTGTGATCACC Tgfbr3/SF-1 ChIP qPCR F CCGGAATCCAAGAAGATTGA Rpl19 R TCAGCTTGTGTGATGTGTCT Tgfbr3/SF-1 ChIP qPCR F TCAGTACCACCAAGAGGTTA TGfbr3/SF-1 ChIP qPCR R GTACCCAGCACCTCTAGGT Gene desert qPCR R GCACACAGACCAAGGGTTAA  Gene desert qPCR R GCACACCAGTGCCTTTGA GGGGACGGACGAAGGTTTA Gene desert qPCR R GCACACCAGTGCCTCTAGGT GGRIC F GGACATGTTCAGGGACGACGCT GGRIC F GGACATGTTCAGGGACGACGCT GGRIC F GGACATGTTCAGGGACGACGCT GGRIC F GGACATGTTCAGGGACGACGCT GGACGGACGAGGTTTA GGENC GGACAGACCAGGCCC GGACACCAGTGCCTTAGAT GGACGCAGGCGACGAGGCT GGACGGACGAACACCAGGCCC TGGGACGAGACCACCAGGCC GGACGAGGCGACACACCCC TGGGGACGACCACCAGGC GRIC F GGACATGTTCAGACCAGGCACACCCT GGACACCAGTGCCAAGGCACCCC TGGGACGAGGCACACCCCT GGACACCAGTGCCAAGGCACCCC TGGGACAGACCACCAGGCCACACGCCCCCAAGGC GRIC F GGACATGTCACACAAGACACCAAGGCAAAGCATAGCT ACAAGGTGTAATCCAACAAGGCAAGG			
R   Human Tgfbr3I promoter amplification   AAAACTCGAGTAGGCGTAGCATCCCTCTC   F   996/+1 promoter amplification   TTTTAAGCTTGGACCAGCTGAGGTCGGA   R   Tgfbr3I/TGFBR3L mutagenesis   TTTTAAGCTTGGACCAGTGAGGTCAGA   TTTTAAGCTTGGACCAGTGAGGTCAGA   TTTTAAGCTTGGACCAGTGAGGTCAGA   TTTTAAGCTTGGACCAGTGAGGTCAGA   TTTTAAGCTTGGACCAGTGAATTCCAGGCATAAGGGC   Tgfbr3I SF-1 site 1 mut F   GCCCTTATCCATGGCTGGAATTGAGACATGTCCTAGAT   Tgfbr3I SF-1 site 2 mut F   GGTGGCAGCCTCACCAATTCCAGGGCTACC   Tgfbr3I SF-1 site 2 mut F   GGTGGCAGCCTCACCAATTCCAGGGCTACC   TGFBR3L SF-1 site 1 mut F   CCAGAGCCAATGCCCAATTCCTGAGGGGATTAAGGG   TGFBR3L SF-1 site 1 mut R   CCCTTAATCCCTCAGGAATTGGGCATTGCTCTGG   TGFBR3L SF-1 site 2 mut R   TGCCTCCTCAGGAATTGGCAAGAGGGGAGCA   TGFBR3L SF-1 site 2 mut R   TGCCTCCTCTTGCAATTACAGGGCCGC   QPCR primers   Fshb F   GTCGGGCCTTTAATGCAAGAGAGGAGGAGCA   TGFBR3L SF-1 site 2 mut R   TGCCTCCTCTTTGCCAATTACAGGGCGCC   QPCR primers   TCGCTACCTCTTTGTCGT   TCGCTACCTCTTTGTCGT   TCGCTACCTCTTTGTCGT   TCGCTACCTCCTTTGTCGT   TCGCTACCTCCTTTGTCGT   TCGCTACCTCCTTTGTCGT   TCGCTACCTCCTTTGTCGT   TCGCTACCTCCTTTGTCGT   TCGCTACCCTCCTTTGTCGAAAAAAAAAAAAAAAAAAAA	F	AAAACTCGAGGTAGCTGATGCAACCATACGTAG	
-996/+1 promoter amplification F -996/+1 promoter amplification R R  Tgfbr3l/TGFBR3L mutagenesis  Tgfbr3l/SF-1 site 1 mut F Tgfbr3l/SF-1 site 1 mut F Tgfbr3l/SF-1 site 2 mut F Tgfbr3l/SF-1 site 2 mut F Tgfbr3l/SF-1 site 2 mut F TgFBR3L SF-1 site 1 mut F TGCAGCCCTGGAATTCCAGGCCTCACC TGFBR3L SF-1 site 1 mut F TGCAGCCCTGGAATTGGTGAGGGTTAAGGG TGFBR3L SF-1 site 1 mut F TGCAGCCCTAGCAATTCCTGAGGGGATTAAGGG TGFBR3L SF-1 site 1 mut R TGCCTCCTCAGGAATTGGTGAGGGATTAAGGG TGFBR3L SF-1 site 2 mut R TGCCTCCTCTTGCCAATTCCAGGGGATTAAGGG TGFBR3L SF-1 site 2 mut R TGCCTCCTCTTGCCAATTCCAGGGGCTCCTGG TGFBR3L SF-1 site 2 mut R TGCCTCCTCTTGCCAATTCCAGGGGCCCC  QPCR primers  Fshb F TCAGGGGCTACTGCTACACT TShb R CAGGCAATCTTACGGTCTCG TGhhr F TCAGCTACCTCCTTTGTCGT TGCTTGCTTCAAGTTCCC TGhhr R CACGGGTTAGGAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R ACAGGTGTAATCCAACAGGGCAG  Nr5a1 F AGGAGTTCGTCTCAAGTTCCT TGTbr3l F CCGGAATCCAAGAAGATTGA Rpl19 R TTCAGCTTGTGGTAACG TCAGGGCAGCCTTTAAC TGBr3l F CCGGAATCCAAGAAGATTGA TGBr3l F CCTGACACCAGTGCCTTTGA TGBr3l F CCTGACACCAGTGCCTTTGA TGBr3l F TCAGTTAGGAAGCCC TGTBR3l SF-1 ChIP qPCR F TCAGTACATCAAGAAGCTT TGBR3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR R CCCAAAGCCAGTACTCAAGTTCC GCATAACCAGGGCAG GRIC R GCATAACCAGTGCCTTTGATGCTG  GCATAACCAGTGCATTACCAGGCCC GCATAACCAGGGCCAGC GRIC R GCATAACCAGTGCATTCCT Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG GRIC R GCATAACCAGTGCATTGCTG Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG		AAAAAAGCTTGACCGGCAGCGAGCACCT	
F-996/+1 promoter amplification R  Tgfbr3l/TGFBR3L mutagenesis  Tgfbr3l/SF-1 site 1 mut F ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGCTGfbr3l/SF-1 site 1 mut R GCCCTTATCCATGCGTGGAATTGAGCATGTCCAGATTGfbr3l/SF-1 site 2 mut F GGTGGCAGCCTCACCAATTCCAGGCCTACCATTGGTCAGATTGfbr3l/SF-1 site 2 mut F GGTGGCAGCCTGGAATTGGTGAGGCTGCACC  Tgfbr3l/SF-1 site 2 mut F GGTGGCAGCCTGGAATTGGTGAGGCTACC  TGFBR3L/SF-1 site 1 mut F CCAGAGCCAATGCCCAATTCCTGAGGGGATTAAGGG  TGFBR3L/SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGGCATTGGCTCTGG  TGFBR3L/SF-1 site 2 mut R TGCCTCCTCAGGAATTGGCCATTGGCTCTGG  TGFBR3L/SF-1 site 2 mut R TGCCTCCCTCAGGAATTGGCCACC  QPCR primers  Fshb F GTGCGGGCTACACACT  Fshb R CAGGCAATCTACACT  Fshb R CAGGCAATCTACACT  Gnrhr F TTCGCTACCTCTTTGTCGT  Gnrhr F TTCGCTACCTCCTTTTGTCGT  Gnrhr R CACGGGTTAAGAAACACAAA  Lhb F ACTGTGCCGGCCTGTCAACG  Lhb R AGCAGCCGGCAGTACTCGAA  Nr5a1 F AGCAGCGGCAGAACTCCGA  Nr5a1 F AGCAGCTGTAATCAGGGCAG  Rpl19 F CGGGAATCCAAGAAGATTGA  Rpl19 R TTCAGCTTGTGTGTCTCAAGTTCCT  Tgfbr3l/SF-1 ChIP qPCR F TCAGTACACAGAAAAACACAAAAAAAAAAAAAAAAAAAA	Human Tgfbr3I promoter ampli	fication	
R Tgfbr3/TGFBR3L mutagenesis Tgfbr3/SF-1 site 1 mut F Tgfbr3/SF-1 site 1 mut R GCCCTTATCCATGGCTGGAATTGAGCACATGCTCAGAT Tgfbr3/SF-1 site 1 mut R GCCCTTATCCATGGCTGGAATTGAGCACATGCTCAGAT Tgfbr3/SF-1 site 2 mut F GGTGGCAGCCTCACCAATTCCAGGGCTACC Tgfbr3/SF-1 site 2 mut R GGTAGCCCTGGAATTGGTGAGGCTGCCACC Tgfbr3/SF-1 site 1 mut F CCAGAGCCCAATGCCCAATTCCTGAGGGGATTAAGGG TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGGCATTGGGCATTGGGGGTATAAGGG TGFBR3L SF-1 site 2 mut F GGCGGCCCTGTAATTGGCAAGGAGGGGAGGCA TGFBR3L SF-1 site 2 mut R TGCCTCCCTCCTTGCCAATTACAGGGCATTGGCCA TGFBR3L SF-1 site 2 mut R TGCCTCCCTCCTTGCCAATTACAGGGCCACC  QPCR primers Fshb F GTCCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGCGCAGTACTCGGA Nr5a1 F AGGAGTTCGTCTCAAGTTCCT Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG Rpl19 F CGGGAATCCTAAGAAGATTGA Rpl19 R TTCAGCTTGTGGAAAGAAGAAA Rpl19 R TTCAGCTTGTGGAACGAAA TGfbr3/SF-1 ChIP qPCR F TCAGTACACCAGTGCTTTGA Tgfbr3/SF-1 ChIP qPCR R GTACCCAGCCCTCTTAGGT Gene desert qPCR R GCACACCAGGACCAGAACGCAAA GCAGCCAAACGCAAAGGTTTA Gene desert qPCR R GGACATGTTCAGGGAACCAGGC GRIC R GCATAACCAGGGATCCAAGGCC GRIC R GCATAACCAGTGAAACACAGCATCG GRIC R GCATAACCAGTGAAACACAGGCCAG GRIC R ACAAGGTTCAAGTTCCT Nr5a1 R ACAAGGTTCATCAGGTTGCTCAAGTTCC CACAAACACAGGGCAGC GRIC R GCATAACCAGTGAAACACACTCAAGTTCAAGTACG GCATAACCAGTGCCTTTGA TGGATTGCTTGCTTGCTTGCTTAGT GCATCAGTTCATCAGTTCATCAGTTCC CACAAACCAGGAACACCATACTCAGTTAGT GCACCAGGCCTCTTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCTCTAGGT GCACCAGGCCCTCTAGGT GCACCAGGCCCTCTAGGT GCACCAGGCCCTCTAGGT GCACCAGGCCCTCTAGGT GCACCAGGCCCTCTAGGT GCACCAGGCCCCCCCCCC	·	AAAACTCGAGTAGGCGTAGCATCCCTCTC	
Tgfbr3/TGFBR3L mutagenesis Tgfbr3/ SF-1 site 1 mut F ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGC Tgfbr3/ SF-1 site 1 mut R GCCCTTATCCATGGCTGAATTGAGCACTGTCTCAGAT Tgfbr3/ SF-1 site 2 mut F GGTGGCAGCCTCACCAATTCCAGGGCTACC Tgfbr3/ SF-1 site 2 mut R GGTAGCCCTGGAATTGGTGAGCTCCACC TGFBR3L SF-1 site 1 mut F CCAGAGCCAATGCCCAATTCCTGAGGGATTAAGGG TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGTGGCGTTCTGG TGFBR3L SF-1 site 2 mut F GGCGGCCCTGTAATTGGCAAGGAGGAGGAGCA TGFBR3L SF-1 site 2 mut R TGCTCCCTCTTGCCAATTACAGGGCATTGGCTCTGG TGFBR3L SF-1 site 2 mut R TGCTCCCTCTTGCCAATTACAGGGCCCC TGFBR3L SF-1 site 2 mut R TGCTCCCTCTTGCCAATTACAGGGCCCCC TGFBR3L SF-1 site 2 mut R TGCTCCCTCTTTGCCAATTACAGGGCCCCC TGCTTAATTCGCAATTACAGGGCCCCC TGCTTTGCCAATTACAGGGCCCCCC TGCTTTGCCAATTACAGGGCCCCCCCCCC	-996/+1 promoter amplification	TTTTAAGCTTGGACCAGCTGAGGTCGGA	
Tgfbr3/SF-1 site 1 mut F         ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGC           Tgfbr3/SF-1 site 1 mut R         GCCCTTATCCATGGCTGGAATTGAGCATGTCCTCAGAT           Tgfbr3/SF-1 site 2 mut F         GGTGGCAGCCTCACCATTCCTGAGGCTCACC           Tgfbr3/SF-1 site 2 mut R         GGTAGCCCTGGAATTGGTGAGGCTGCCACC           TGFBR3L SF-1 site 1 mut F         CCAGAGCCAATGCCCAATTCCTGAGGGGATTAAGGG           TGFBR3L SF-1 site 1 mut R         CCCTTAATCCCCTCAGGAATTGGCATGGCTCTGG           TGFBR3L SF-1 site 2 mut F         GGCGGCCCTGTAATTGGCAAGGAGGAGGAGCA           TGFBR3L SF-1 site 2 mut R         TGCCTCCCTCCTCTGCCAATTACAGGGCCGCC           qCR primers         Fshb F         GTGCGGGCTACTGCTACACT           Fshb R         CAGGGATACTTCACCTCTTTGTCGT           Gnrhr F         TTCGCTACCTCCTTTGTCGT           Gnrhr F         ACTGTGCCGGCCTGTCAACG           Lhb R         ACTGTGCCGGCCTGTCAACG           Lhb R         ACTGTGCCGGCCTGTCAACG           Lhb R         ACAGGTTAGCTCTGTCTCAAGTTCCT           Nr5a1 F         ACAGGTTCATCTCTGTCTCAAGTTCCT           Nr5a1 R         ACAAGGTGAACAAAAAAAAAAAAAAAAAAAAAAAAAAAA			
Tgfbr3/SF-1 site 1 mut R         GCCCTTATCCATGGCTGAATTGAGCATGTGCTCAGATTGBT3 SF-1 site 2 mut F         GGTGGCAGCCTCACCAATTCCAGGGCTACC           Tgfbr3/SF-1 site 2 mut R         GGTAGCCTGACAATTGATGAGCTGCCACC           TGFBR3L SF-1 site 1 mut F         CCAGAGCCAATTGCTGAGGGGATTAAGGG           TGFBR3L SF-1 site 1 mut R         CCCTTAATCCCCTCAGGAATTGGCCATTGGCTCTGG           TGFBR3L SF-1 site 2 mut F         GGCGGCCTGTAATTGGCAAGGAGGGAGCA           TGFBR3L SF-1 site 2 mut R         TGCCTCCCTCCTTGCCAATTACAGGGCCGCC           qPCR primers         GTGCGGGCTACTGCTACACT           Fshb F         GTGCGGGCTACTGCTACACT           Fshb R         CAGGCAATCTTACGGTCTCG           Gnrhr F         TTCGCTACCTCCTTTGTCGT           Gnrhr R         CACGGGTTAGGAAAGCAAA           Lhb F         ACTGTGCCGGCCTGTCAACG           Lhb R         AGCAGCCGGCAGTACTCGGA           Nr5a1 F         ACAAGGTGTAATCCAACAGGGCAG           Rpl19 F         CGGGAATCCAAGAAGATTCCT           Rpl19 R         TTCAGCTTGTGTCTCAAGTTCCT           Tgfbr3/ R         CCTGACACCAGTGCCTTTGA           Tgfbr3/ SF-1 ChIP qPCR F         CCTGACACCAGTGCCTTTGA           Tgfbr3/ SF-1 ChIP qPCR R         GTACCCAGCCTCTAGGT           Gene desert qPCR R         GTACCCAGCCCTCTAGGT           Gene desert qPCR R         CCCAAAGTCATGTTGTACTTGATAG			
Tgfbr3/SF-1 site 1 mut R         GCCCTTATCCATGGCTGAATTGAGCATGTGCTCAGATTGBT3 SF-1 site 2 mut F         GGTGGCAGCCTCACCAATTCCAGGGCTACC           Tgfbr3/SF-1 site 2 mut R         GGTAGCCTGACAATTGATGAGCTGCCACC           TGFBR3L SF-1 site 1 mut F         CCAGAGCCAATTGCTGAGGGGATTAAGGG           TGFBR3L SF-1 site 1 mut R         CCCTTAATCCCCTCAGGAATTGGCCATTGGCTCTGG           TGFBR3L SF-1 site 2 mut F         GGCGGCCTGTAATTGGCAAGGAGGGAGCA           TGFBR3L SF-1 site 2 mut R         TGCCTCCCTCCTTGCCAATTACAGGGCCGCC           qPCR primers         GTGCGGGCTACTGCTACACT           Fshb F         GTGCGGGCTACTGCTACACT           Fshb R         CAGGCAATCTTACGGTCTCG           Gnrhr F         TTCGCTACCTCCTTTGTCGT           Gnrhr R         CACGGGTTAGGAAAGCAAA           Lhb F         ACTGTGCCGGCCTGTCAACG           Lhb R         AGCAGCCGGCAGTACTCGGA           Nr5a1 F         ACAAGGTGTAATCCAACAGGGCAG           Rpl19 F         CGGGAATCCAAGAAGATTCCT           Rpl19 R         TTCAGCTTGTGTCTCAAGTTCCT           Tgfbr3/ R         CCTGACACCAGTGCCTTTGA           Tgfbr3/ SF-1 ChIP qPCR F         CCTGACACCAGTGCCTTTGA           Tgfbr3/ SF-1 ChIP qPCR R         GTACCCAGCCTCTAGGT           Gene desert qPCR R         GTACCCAGCCCTCTAGGT           Gene desert qPCR R         CCCAAAGTCATGTTGTACTTGATAG	Tgfbr3l SF-1 site 1 mut F	ATCTGAGCACATGCTCAATTCCAGCCATGGATAAGGGC	
Tgfbr3l SF-1 site 2 mut F Tgfbr3l SF-1 site 2 mut R GGTGGCAGCCTGACCAATTCCAGGGCTACC Tgfbr3l SF-1 site 1 mut F CCAGAGCCAATTGCCCACC TGFBR3L SF-1 site 1 mut F CCAGAGCCAATGCCCAATTGGCCAATTGGCTCTGG TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGCCATTGGCTCTGG TGFBR3L SF-1 site 2 mut F GGCGGCCCTGTAATTGGCAAGGAGGGAGGCA TGFBR3L SF-1 site 2 mut R TGCCTCCTCCTTGCCAATTACAGGGCCGC  qPCR primers  Fshb F GTGCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr F TTCGCTACCTCTTTTGTGT Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA Nr5a1 F AGCAGCCGGCAGTACTCGGA Nr5a1 F AGCAGCCGGCAGTACTCGGA Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG Rpl19 F CGGGAATCCAAGAAGATTGA Rpl19 F CGGGAATCCAAGAAGATTGA TTCAGCTTGTGGTGTC Tgfbr3l F CCTGACACCAGTGCTTTGA Tgfbr3l SF-1 ChIP qPCR F TCAGTACACAAGAGATTA Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR R GTACCCAGCACTAGTTGTAAG Gene desert qPCR R GGACATGTTCAGGATCCAAGG GGRIC R GRIC F GGACATGTTCAGGATCCCAGGC GRIC R GGACATGTTCAGGATCCAAGGA GGACTTCAAGAAACCCA GGGACTTTGA GGACACCAGGTTTAA GGACTTCAAGAAACCCC TGfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT GGACATACTCAGGAAACGCCC TGfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT GGACATGTTGATAG GGACATGTTCAGGGATCGCCAGGC GRIC R GGACATGTTCAGGGATCGCCAGGC GRIC R GGACATGTTCAGGGATCGCCAGGC GRIC R GGACATGTTCAGGGATCGCCAGGC GRIC R GCATAACCAGTGCAACAGGATTCCC Nr5a1 R ACAAGGTTCACACAGGGCAG		GCCCTTATCCATGGCTGGAATTGAGCATGTGCTCAGAT	
Tgfbr3l SF-1 site 2 mut R         GGTAGCCCTGGAATTGGTGAGGCTGCCACC           TGFBR3L SF-1 site 1 mut F         CCAGAGCCAATGCCCAATTCCTGAGGGGATTAAGGG           TGFBR3L SF-1 site 1 mut R         CCCTTAATCCCCTCAGGAATTGGCCATTGGCTCTGG           TGFBR3L SF-1 site 2 mut F         GGCGGCCCTGTAATTGGCAAGGAGGAGGCA           TGFBR3L SF-1 site 2 mut R         TGCCTCCCTCCTTGCCAATTACAGGGCCGCC           qPCR primers         GTGCGGGCTACTGCTACACT           Fshb F         GTGCGGGCTACTGCTACACT           Fshb R         CAGGCAATCTTACGGTCTCG           Gnrhr F         TTCGCTACCTCCTTTGTCGT           Gnrhr R         CACGGGTTTAGGAAAGCAAA           Lhb F         ACTGTGCCGGCCTGTCAACG           Lhb R         AGCAGCCGGCAGTACTCGGA           Nr5a1 F         AGGAGTTCGTCTGTCTCAAGTTCCT           Nr5a1 R         ACAAGGTGTAATCCAACAGGGCAG           Rpl19 F         CGGGAATCCAAGAAGATTGA           Rpl19 R         TTCAGCTTGTGGATGTGCTC           Tgfbr3l R         CTAGGGGACGACGATTTGA           Tgfbr3l SF-1 ChIP qPCR F         TCAGTACATCAAGAAAGCCC           Tgfbr3l SF-1 ChIP qPCR R         GTACCAGCCTCTAGGT           Gene desert qPCR R         GTACCAAGAAACGCAAAGGTTTA           Gene desert qPCR R         GCCAAAGTCATGTTGACTTGATAG           Gene desert qPCR R         GCCAAAGTCATGTTGACTGAGACAGCATTGCTG     <		GGTGGCAGCCTCACCAATTCCAGGGCTACC	
TGFBR3L SF-1 site 1 mut F CCAGAGCCAATGCCCAATTCCTGAGGGGATTAAGGG TGFBR3L SF-1 site 1 mut R CCCTTAATCCCCTCAGGAATTGGCCTCTGG TGFBR3L SF-1 site 2 mut F GGCGCCCTGTAATTGGCAAGGAGGGAGGCA TGFBR3L SF-1 site 2 mut R TGCCTCCCTCCTTGCCAATTACAGGGCCGCC  qPCR primers  Fshb F GTGCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr F TTCGCTACCTCCTTTGTCGT Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA Nr5a1 F AGCAGCCGGCAGTACTCGGA Nr5a1 F ACAAGGTGTAATCCAACAGGGCAG Rpl19 F CGGAATCCAAGAAAATTCAACAGGGCAG Rpl19 R TTCAGCTTGTGGATTGGCTC Tgfbr3l F CCTGACACCAGTGCCTTTGA Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAAGCCC Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR R GCACAAGTCAAGAAAGCCAAGGGTTTA Gene desert qPCR R GCACAAGTCAAGAAACGCAAAGGTTTA GGACACAGTGCTTTGATAG Genotyping primers GRIC F GGACATCCAAGGAACACAGTTGCTG Nr5a1 R ACAAGGTTCAACAGAACACAGTGCCT GRIC R GCATAACCAGTGAACAGCAGTGCCT GRIC R GCATAACCAGTGAACAGCAGTGCCT Rr5a1 R ACAAGGTTCAACAGAACAGCAGGCAGGC GRIC R GCATAACCAGTGAAACAGCATTGCTG Nr5a1 R ACAAGGTTCAACAGAACAGCAAGGTTCC Nr5a1 R ACAAGGTTCAACCAGTGCCAGGC ACAAGGTTCCTCTCAAGTTCC Nr5a1 R ACAAGGTTCAACCAGGGCAG			
TGFBR3L SF-1 site 1 mut R TGFBR3L SF-1 site 2 mut F GGCGGCCTGTAATTGGCAAGGAGGCA TGFBR3L SF-1 site 2 mut R TGCCTCCTCCTTGCCAATTACAGGGCCGC  qPCR primers  Fshb F GTGCGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr F TTCGCTACCTCTTTGCGAATTACAGGGCCGC CAGGCAATCTTACGGTCTCG Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R ACGAGCCGGCAGTACTCGTACACG Lhb R ACGAGCCGGCAGTACTCGAACG ACAGAGTTCACACG ACAGAGTTCACACG ACAGAGTTCACACG ACAGAGTTCACACG ACAGAGAGTTCACACG ACAGAGTTCACACG ACAGAGTTCACACG ACAGAGTTCACACACG ACAGAGAGTTCCT ACAGAGTTCACACACG ACAGAGAGTTCACACACG ACAGAGAGTTCACACACACGCACC ACAGACACACACACACACC ACAGACACCACTCCTTTCACACTCCT ACAGAGTTCACTCCTCTCCCTCCTCCCTCCCTCCCTCCCT			
TGFBR3L SF-1 site 2 mut F TGFBR3L SF-1 site 2 mut R TGCCTCCCTCCTTGCCAATTACAGGGCGCC  qPCR primers Fshb F GTGCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr F TTCGCTACCTCCTTTGTCGT Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA Nr5a1 F AGGAGTTCGTCTCTCTTGTCT Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG Rpl19 F CGGGAATCCAAGAAGATTGA Rpl19 R TTCAGCTTGTGTGTCTCAAGTTCCT Tgfbr3l F CCTGACACCAGTGCTTTGA Tgfbr3l SF-1 ChIP qPCR F TCAGTACACAGAAAGCC Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCTCTAGGT Gene desert qPCR R GTACCAAGAAACGCAAAGGTTAAC Genotyping primers GRIC F GGACATCCTAAGTTCCC Nr5a1 R ACAAGGTTCAAGAACGCAGCC RGIC R GCATAACCAGTGAAACAGGCC GRIC R GCATAACCAGTGAAACAGCAGCC Nr5a1 R ACAAGGTTTCAAGTTCC ACAAGGTTCAAGTTCC ACAAGGTTCAACAGGCCAGC ACAAGGTTCCTCAAGTTCC ACAAGGTTCAACAGGCCAGC ACAAGGTTCAACAGGCCAGC ACAAGGTTCAACAGGCCAGC ACAAGGTTCCTCAAGTTCC ACAAGGTTCAACAGGCCAGCC ACAAGGTTCAACAGGCCAGC			
TGFBR3L SF-1 site 2 mut R  GCCTCCCTCCTTGCCAATTACAGGGCCGCC  GPCR primers  Fshb F  GTGCGGGCTACTGCTACACT  Fshb R  CAGGCAATCTTACGGTCTCG  Gnrhr F  TTCGCTACCTCCTTTGTCGT  Gnrhr R  CACGGGTTTAGGAAAGCAAA  Lhb F  ACTGTGCCGGCCTGTCAACG  Lhb R  AGCAGCCGGCAGTACTCGA  Nr5a1 F  AGCAGCCGGCAGTACTCGA  Nr5a1 R  ACAAGGTGTAATCCAACAGGGCAG  Rpl19 F  CGGGAATCCAAGAAGATTGA  Rpl19 R  TTCAGCTTGTGGATGTCTC  Tgfbr3l F  CCTGACACCAGTGCTTTGA  Tgfbr3l SF-1 ChIP qPCR F  TCAGTACATCAAGAAAGCC  Tgfbr3l SF-1 ChIP qPCR R  GTACCCAGCCCTCTAGGT  Gene desert qPCR R  GTACCCAGCACAAGAAGTTTA  Gene desert qPCR R  GCACAAGTCATGTTGTACTTGATAG  Genotyping primers  GRIC F  GGACATGTTCAGGGATCCC  Nr5a1 R  ACAAGGTTCAAGTCCAAGATTCC  Nr5a1 R  ACAAGGTTCAAGTCCAAGTTCC  Nr5a1 R  ACAAGGTTCAAGTTCCAAGTTCC  Nr5a1 R			
QPCR primers           Fshb F         GTGCGGGCTACTGCTACACT           Fshb R         CAGGCAATCTTACGGTCTCG           Gnrhr F         TTCGCTACCTCCTTTGTCGT           Gnrhr R         CACGGGTTTAGGAAAGCAAA           Lhb F         ACTGTGCCGGCCTGTCAACG           Lhb R         AGCAGCCGGCAGTACTCGGA           Nr5a1 F         AGGAGTTCGTCTCTCAAGTTCCT           Nr5a1 R         ACAAGGTGTAATCCAACAGGGCAG           Rpl19 F         CGGGAATCCAAGAAGATTGA           Rpl19 R         TTCAGCTTGTGGATGTGCTC           Tgfbr3l F         CCTGACACCAGTGCCTTTGA           Tgfbr3l SF-1 ChIP qPCR F         TCAGTACATCAAGAAAGCCC           Tgfbr3l SF-1 ChIP qPCR R         GTACCCAGCCCTCTAGGT           Gene desert qPCR R         GTACCAGCACTCTAGGT           Gene desert qPCR R         CCCAAAGTCATGTTGTACTTGATAG           Gene desert qPCR R         CCCAAAGTCATGTTGTACTTGATAG           Genotyping primers         GGACATGTTCAGGGATCGCCAGGC           GRIC R         GCATAACCAGTGAAACAGCATTGCTG           Nr5a1 F         AGGAGTTCGTCTGTCTCAAGTTCC           Nr5a1 R         ACAAGGTGTAATCCAACAGGCAG			
Fshb F GTGCGGGCTACTGCTACACT Fshb R CAGGCAATCTTACGGTCTCG Gnrhr F TTCGCTACCTCCTTTGTCGT Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA Nr5a1 F AGGAGTTCGTCTCAAGTTCCT Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG Rpl19 F CGGAATCCAAGAAGATTGA Rpl19 R TTCAGCTTGTGGATGTCC Tgfbr3l F CCTGACACCAGTGCCTTTGA Tgfbr3l R CTAGGGGACGACGAGTAT Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAGCCC Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCACTTTA Gene desert qPCR R GTACCCAGCACAGTTACTTAC Genotyping primers GRIC F GGACATGTTCAAGTTCC Nr5a1 R ACAAGGTTCATCTCAAGTTCC Nr5a1 R ACAAGGTTCATCTCAAGTTCC Nr5a1 R ACAAGGTTCATCTCAAGTTCC Nr5a1 R ACAAGGTTCAACAAGACGCAGC Nr5a1 R ACAAGGTTCAACAAGAGCCC			
Fshb R Gnrhr F TTCGCTACCTCCTTTGTCGT Gnrhr R CACGGGTTTAGGAAAGCAAA Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA Nr5a1 F AGGAGTTCGTCTCAACGGGAAGCAGGAAGCAAA Rpl19 F CGGGAATCCAAGAGAGATGAACGAAGCAGAAGAACAACACACAC		GTGCGGGCTACTGCTACACT	
Gnrhr F Gnrhr R CACGGGTTTAGGAAAGCAAA  Lhb F ACTGTGCCGGCCTGTCAACG  Lhb R AGCAGCCGGCAGTACTCGGA  Nr5a1 F AGGAGTTCGTCTGTCTCAAGTTCCT  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG  Rpl19 F CGGGAATCCAAGAAGATTGA  Rpl19 R TTCAGCTTGTGATGTCTC  Tgfbr3l F CCTGACACCAGTGCCTTTGA  Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAGCCC  Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCTCTAGGT  Gene desert qPCR R GTACCCAGAAACGCAAAGGTTTA  Gene desert qPCR R CCCAAAGTCATGTTGATTTAACG  Genotyping primers  GRIC F GGACATGTTCAGGGATCGCAGGC  Rr5a1 F AGGAGTTCGTCTCTCAAGTTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
CACGGGTTTAGGAAAGCAAA			
Lhb F ACTGTGCCGGCCTGTCAACG Lhb R AGCAGCCGGCAGTACTCGGA  Nr5a1 F AGGAGTTCGTCTCAAGTTCCT  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG  Rpl19 F CGGAATCCAAGAAGATTGA  Rpl19 R TTCAGCTTGTGGATGCTC  Tgfbr3l F CCTGACACCAGTGCCTTTGA  Tgfbr3l R CTAGGGGACGACGACGATAT  Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAGCCC  Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT  Gene desert qPCR R CCCAAGACCAAGGTTTA  Gene desert qPCR R CCCAAAGTCATGTTGATAG  Genotyping primers  GRIC F GGACATGTTCAGGGATCGCCAGGC  GRIC R GCATAACCAGTGAAACAGCATTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
Lhb RAGCAGCCGGCAGTACTCGGANr5a1 FAGGAGTTCGTCTCTCAAGTTCCTNr5a1 RACAAGGTGTAATCCAACAGGGCAGRpl19 FCGGGAATCCAAGAAGATTGARpl19 RTTCAGCTTGTGGATGTCCTgfbr3/ FCCTGACACCAGTGCCTTTGATgfbr3/ RCTAGGGGACGACGAGGTATTgfbr3/ SF-1 ChIP qPCR FTCAGTACATCAAGAAAGCCCTgfbr3/ SF-1 ChIP qPCR RGTACCCAGCCCTCTAGGTGene desert qPCR FGTCACAGAAACGCAAAGGTTTAGene desert qPCR RCCCAAAGTCATGTTGTACTTGATAGGenotyping primersGGACATGTTCAGGGATCGCCAGGCGRIC FGGACATGTTCAGGGATCGCCAGGCGRIC RGCATAACCAGTGAAACAGCATTGCTGNr5a1 FAGGAGTTCGTCTGTCTCAAGTTCCNr5a1 RACAAGGTGTAATCCAACAGGGCAG			
Nr5a1 FAGGAGTTCGTCTGTCTCAAGTTCCTNr5a1 RACAAGGTGTAATCCAACAGGGCAGRpl19 FCGGGAATCCAAGAAGATTGARpl19 RTTCAGCTTGTGGATGTCTCTgfbr3l FCCTGACACCAGTGCCTTTGATgfbr3l RCTAGGGGACGACGAGGTATTgfbr3l SF-1 ChIP qPCR FTCAGTACATCAAGAAAGCCCTgfbr3l SF-1 ChIP qPCR RGTACCCAGCCCTCTAGGTGene desert qPCR FGTCACAGAAACGCAAAGGTTTAGene desert qPCR RCCCAAAGTCATGTTGTACTTGATAGGenotyping primersGRIC FGGACATGTTCAGGGATCGCCAGGCGRIC RGCATAACCAGTGAAACAGCATTGCTGNr5a1 FAGGAGTTCGTCTGTCTCAAGTTCCNr5a1 RACAAGGTGTAATCCAACAGGGCAG			
Nr5a1 RACAAGGTGTAATCCAACAGGGCAGRpl19 FCGGGAATCCAAGAAGATTGARpl19 RTTCAGCTTGTGGATGTGCTCTgfbr3l FCCTGACACCAGTGCCTTTGATgfbr3l SFCTAGGGGACGACGAGGTATTgfbr3l SF-1 ChIP qPCR FTCAGTACATCAAGAAAGCCCTgfbr3l SF-1 ChIP qPCR RGTACCCAGCCCTCTAGGTGene desert qPCR FGTCACAGAAACGCAAAGGTTTAGene desert qPCR RCCCAAAGTCATGTTGTACTTGATAGGenotyping primersGRIC FGGACATGTTCAGGGATCGCCAGGCGRIC RGCATAACCAGTGAAACAGCATTGCTGNr5a1 FAGGAGTTCGTCTGTCTCAAGTTCCNr5a1 RACAAGGTGTAATCCAACAGGGCAG			
Rpl19 F Rpl19 R TTCAGCTTGTGGATGTCTC Tgfbr3l F CCTGACACCAGTGCCTTTGA Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAAGCCC Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR F GCCAAAGTCATGTTGTACTTGATAG Genotyping primers GRIC F GGACATGTTCAGGGATCGCAGGC GRIC R Nr5a1 F AGGAGTTCATCTCTCAAGTTCC Nr5a1 R  CCGGGAATCCAAGAAGATTGAT TTCAGCTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTGATAGATGTTCAGGGATCGCCAGGCAGAACAGATTGCTGATAGATTGATAGATTCCAACAGTGAAACAGCATTGCTGAAGATAGAT			
TTCAGCTTGTGGATGTGCTC     Tgfbr3l F   CCTGACACCAGTGCCTTTGA     Tgfbr3l R   CTAGGGGACGACGAGGTAT     Tgfbr3l SF-1 ChIP qPCR F   TCAGTACATCAAGAAAGCCC     Tgfbr3l SF-1 ChIP qPCR R   GTACCCAGCCCTCTAGGT     Gene desert qPCR F   GTCACAGAAACGCAAAGGTTTA     Gene desert qPCR R   CCCAAAGTCATGTTGTACTTGATAG     Genotyping primers     GRIC F   GGACATGTTCAGGGATCGCCAGGC     GRIC R   GCATAACCAGTGAAACAGCATTGCTG     Nr5a1 F   AGGAGTTCGTCTCTCAAGTTCC     Nr5a1 R   ACAAGGTGTAATCCAACAGGGCAG			
Tgfbr3l F CCTGACACCAGTGCCTTTGA  Tgfbr3l R CTAGGGGACGACGAGGTAT  Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAAGCCC  Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT  Gene desert qPCR F GTCACAGAAACGCAAAGGTTTA  Gene desert qPCR R CCCAAAGTCATGTTGTACTTGATAG  Genotyping primers  GRIC F GGACATGTTCAGGGATCGCCAGGC  GRIC R GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAGC			
Tgfbr3l R  Tgfbr3l SF-1 ChIP qPCR F  TCAGTACATCAAGAAAGCCC  Tgfbr3l SF-1 ChIP qPCR R  GTACCCAGCCCTCTAGGT  Gene desert qPCR F  GTCACAGAAACGCAAAGGTTTA  Gene desert qPCR R  CCCAAAGTCATGTTGTACTTGATAG  Genotyping primers  GRIC F  GGACATGTTCAGGGATCGCCAGGC  GRIC R  GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F  ACAAGGTGTAATCCAACAGGGCAG			
Tgfbr3l SF-1 ChIP qPCR F TCAGTACATCAAGAAAGCCC Tgfbr3l SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR F GCCAAAACGCAAAGGTTTA Gene desert qPCR R CCCAAAGTCATGTTGTACTTGATAG Genotyping primers GRIC F GGACATGTTCAGGGATCGCCAGGC GRIC R GCATAACCAGTGAAACAGCATTGCTG Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
Tgfbr3I SF-1 ChIP qPCR R GTACCCAGCCCTCTAGGT Gene desert qPCR F GCCAAAGTCATGTTGTACTTGATAG Gene desert qPCR R CCCAAAGTCATGTTGTACTTGATAG  Genotyping primers GRIC F GGACATGTTCAGGGATCGCCAGGC GRIC R GCATAACCAGTGAAACAGCATTGCTG Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
Gene desert qPCR F GTCACAGAAACGCAAAGGTTTA Gene desert qPCR R CCCAAAGTCATGTTGTACTTGATAG  Genotyping primers GRIC F GGACATGTTCAGGGATCGCCAGGC GRIC R GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
Gene desert qPCR R  Genotyping primers  GRIC F  GRIC R  GCATAACCAGTGAAACAGCATTGCTG  GRIC R  GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F  AGGAGTTCGTCTGTCTCAAGTTCC  Nr5a1 R  ACAAGGTGTAATCCAACAGGGCAG			
Genotyping primers  GRIC F GGACATGTTCAGGGATCGCCAGGC  GRIC R GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F AGGAGTTCGTCTCTCAAGTTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG			
GRIC F GGACATGTTCAGGGATCGCCAGGC GRIC R GCATAACCAGTGAAACAGCATTGCTG Nr5a1 F AGGAGTTCGTCTCAAGTTCC Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG		CCCAAAGTCATGTTGTACTTGATAG	
GRIC R GCATAACCAGTGAAACAGCATTGCTG  Nr5a1 F AGGAGTTCGTCTCAAGTTCC  Nr5a1 R ACAAGGTGTAATCCAACAGGCAG			
Nr5a1 FAGGAGTTCGTCTCAAGTTCCNr5a1 RACAAGGTGTAATCCAACAGGGCAG			
Nr5a1 R ACAAGGTGTAATCCAACAGGGCAG	GRIC R		
	Nr5a1 F	AGGAGTTCGTCTCTCAAGTTCC	
Nr521 P (recombinant) TCCCTCC \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Nr5a1 R	ACAAGGTGTAATCCAACAGGGCAG	
	Nr5a1 R (recombinant)	TGCGTGCAATCCATCTTGTTCAAT	

# Table 2: DNAP probes


Tgfbr3l SF-1 site 1 WT sense	TATCCATGGCTGGCCTTGAGCATGT
Tgfbr3l SF-1 site 1 WT antisense	ACATGCTCAAGGCCAGCCATGGATA
Tgfbr3l SF-1 site 1 Mut sense	TATCCATGGCTGGAATTGAGCATGT
Tgfbr3l SF-1 site 1 Mut antisense	ACATGCTCAATTCCAGCCATGGATA
Tgfbr3l SF-1 site 2 WT sense	AGCCTCACCAAGGCCAGGGCTACCT
Tgfbr3l SF-1 site 2 WT antisense	AGGTAGCCCTGGCCTTGGTGAGGCT
Tgfbr3l SF-1 site 2 Mut sense	AGCCTCACCAATTCCAGGGCTACCT
Tgfbr3l SF-1 site 2 Mut antisense	AGGTAGCCCTGGAATTGGTGAGGCT
TGFBR3L SF-1 site 1 WT sense	TAATCCCCTCAGGCCTTGGGCATTG
TGFBR3L SF-1 site 1 WT antisense	CAATGCCCAAGGCCTGAGGGGATTA
TGFBR3L SF-1 site 1 Mut sense	TAATCCCCTCAGGAATTGGGCATTG
TGFBR3L SF-1 site 1 Mut antisense	CAATGCCCAATTCCTGAGGGGATTA
TGFBR3L SF-1 site 2 WT sense	CTCCTTGCCAAGGACAGGGCCGCCT
TGFBR3L SF-1 site 2 WT antisense	AGGCGGCCCTGTCCTTGGCAAGGAG
TGFBR3L SF-1 site 2 Mut sense	CTCCTTGCCAATTACAGGGCCGCCT
TGFBR3L SF-1 site 2 Mut antisense	AGGCGGCCCTGTAATTGGCAAGGAG






1 2 165x220 mm (.42 x DPI)

Figure 1



165x191 mm (.42 x DPI)

3



, ,






Figure 4
2 165x206 mm (.42 x DPI)
3





1 Figure 6
2 162x229 mm (.42 x DPI)